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Progestins are synthetic compounds designed to mimic the natural hormone progesterone (Prog), 
and are widely used in hormone replacement therapy (HRT) and contraception. These compounds 
can be divided into four generations, with newer generations increasing in progesterone receptor 
(PR) specificity. Although progestins have many therapeutic benefits, a number of undesirable side-
effects, such as increased risk of breast cancer, have been reported. As a result, many 
postmenopausal women have sought alternatives for HRT, such as compounded bio-identical 
hormones like bio-identical Prog (bProg), claimed not to increase breast cancer risk. Progestins, 
Prog and bProg (collectively referred to as progestogens) elicit their biological effects primarily by 
binding to the PR, which exists as two predominant isoforms, PR-A and PR-B, with PR-B being the 
more transcriptionally active and proliferative isoform in breast cancer. Emerging evidence suggest 
that the PR plays an important role in breast cancer development and progression, and that there is 
crosstalk between the PR and estrogen receptor (ER)-α, a major etiological factor in breast cancer 
biology. Moreover, it has been shown that ER-α is required for PR-B-mediated effects of 
medroxyprogesterone acetate (MPA) on activation of gene expression and breast cancer cell 
proliferation. The latter raised the questions of whether ER-α is needed for PR-B-mediated effects 
of other progestins, and whether the ERβ subtype would also be required. Given that PR-B has both 
transactivation and transrepression functions, this study used transactivation and transrepression 
transcriptional assays to investigate the PR-B-mediated agonist efficacies and potencies of Prog, 
bProg and select progestins from different generations (MPA, norethisterone acetate (NET-A), 
levonorgestrel (LNG), gestodene (GES) and drospirenone (DRSP)), and whether these were 
modulated by ERα and/or ERβ. Furthermore, the effects of the progestogens on breast cancer cell 
proliferation were evaluated in the absence and presence of ERα- and ERβ-specific antagonists. 
Results showed that progestins mostly displayed similar agonist efficacies and potencies for 
transactivation and transrepression via PR-B. The exception was first generation MPA that was less 
efficacious for transactivation and least potent for transrepression, and third generation GES that 
was more potent for transactivation. This study is the first to show that ERα and ERβ differentially 
decreased PR-B-mediated agonist efficacies of progestogens for transactivation and transrepression. 
However, the ERα-specific antagonist had no effect on progestogen-induced expression of the 
endogenous PR-B regulated c-myc gene or repression of the interleukin (IL)-8 gene in the T47D 
breast cancer cell line, while the ERβ-specific antagonist had no effect on progestogen-induced c-
myc gene expression, and appeared to abolish repression of the IL-8 gene. Additionally, we showed 
that all progestogens, except NET-A and DRSP, displayed similar proliferative efficacies and 
potencies for cell proliferation. Interestingly, while the ERα-specific antagonist had no effect on 
progestogen-induced cell proliferation, increased cell proliferation by LNG- and GES was enhanced 
by the ERβ-specific antagonist. Taken together, the results from this study, although having 
limitations, emphasizes the complexity of crosstalk between the PR and ER subtypes in breast 
cancer. Although the physiological implications of these results have to be evaluated, our findings 
may assist us in our understanding of crosstalk between PR-B and the ER subtypes, and how it may 
be contributing to progestin-induced breast cancer cell growth. 





Progestiene is sintetiese verbindings wat ontwerp is om die funksies van die natuurlike hormoon 
progesteroon (Prog) na te boots, en word wêreldwyd in hormoon vervagingsterapie (HVT) en 
voorbehoedmiddels gebruik. Hierdie verbindings kan in vier generasies verdeel word, met die 
nuwer generasie wat meer spesifiek is vir die progesteroon reseptor (PR). Alhoewel progestiene 
baie terapeutiese voordele het, is daar ook verskeie ongewenste newe-effekte, soos verhoogde risiko 
van borskanker, geassosieër met hul gebruik. As gevolg hiervan, het baie na-menopousale vrouens 
alternatiewe begin soek vir HVT, soos byvoorbeeld die saamgestelde bio-identiese hormone soos 
bio-identiese Prog (bProg), wat beweer word om nie die risiko van borskanker te verhoog nie. 
Progestiene, Prog and bProg (gesamentlik verwys daarna as progestogene) voer hul biologiese 
effekte uit deur hoofsaaklik te bind aan die PR, wat voorkom as twee hoof isoforme, PR-A en PR-
B, met PR-B wat hoër transkripsionele aktiwiteit toon en die meer proliferatiewe isoform in 
borskanker is. Onlangse bewyse toon dat die PR ‘n belangrike rol in borskankerontwikkeling en -
bevordering speel, en dat daar ‘n wisselwerking tussen die PR en die estrogeen reseptor (ER)-α, ‘n 
groot etiologiese faktor in borskankerbiologie, voorkom. Verder, is daar gevind dat ERα benodig 
word vir PR-B-bemiddelde effekte van medroksieprogesteroon asetaat (MPA) op die aktivering van 
geentranskripsie en borskanker proliferasie. Die laasgenoemde het gelei tot die vrae of ERα ook 
benodig word vir die PR-B-bemiddelde effekte van ander progestiene, en of die ERβ subtipe ook 
benodig sal word. Gegewe dat PR-B beide transaktivering en transonderdrukking funksies het, is 
daar in hierdie studie gebruik gemaak van transaktivering en transonderdrukking 
transkripsioneletoetse om die PR-B bemiddelde agonis effektiwiteit en potensie van Prog, bProg en 
geselekteerder progestiene van verskillende generasies (MPA, noretisteroon asetaat (NET-A), 
levonorgestrel (LNG), gestodeen (GES) en drospirenoon (DRSP)) te bepaal, asook om vas te stel of 
die effekte deur ERα en/of ERβ gemoduleer word. Verder, is die effekte van die progestogene op 
borskanker proliferasie in die afwesigheid en teenwordigheid van ERα- en ERβ-spesifieke 
antagoniste geëvalueer. Resultate het aangedui dat progestiene meestal soortgelyke agonis 
effektiwiteit en potensies vir transaktivering en transonderdrukking via PR-B getoon het. Die 
uitsonderings was die eerste generasie progestien MPA wat minder effektief vir transaktivering en 
minder potent vir transonderdrukking was, en die derde generasie progestien GES wat meer potent 
vir transaktivering was. Hierdie studie wys vir die eerste keer dat ERα en ERβ die PR-B-
bemiddelde agonis effektiwiteit van die progestogene vir transaktivering en transoderdrukking 
differensieel verminder. Nietemin, het die ERα-spesifieke antagonis geen effek op progestogeen-
geïnduseerde uitdrukking van die endogene PR-B-gereguleerde c-myc geen, of onderdrukking van 
die interleukin (IL)-8 geen in die T47D borskanker sellyn gehad nie, terwyl die ERβ-spesifieke 
antagonis geen effek op c-myc geen uidrukking gehad het nie, en wou dit voorkom asof dit die 
onderdrukking van die IL-8 geen verhoed. Verder het ons gewys dat alle progestogene, behalwe 
NET-A en DRSP, soortgelyke proliferatiewe effektiwiteit en potensies vir selproliferasie getoon 
het. Interessant genoeg, terwyl die ERα-spesifieke antagonis geen effek op progestogeen-
geïnduseerde selproliferasie gehad het nie, is die LNG- en GES-geïnduseerde selproliferasie selfs 
verder verhoog deur die ERβ-spesifieke antagonis. Ten slotte, alhoewel daar sekere beperkinge is, 
beklemtoon die resultate van hierdie studie die kompleksiteit van die wisselwerking tussen PR-B en 
die ER subtipes in borskanker. Alhoewel die fisiologiese implikasies van ons resultate nog 
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geëvalueer moet word, mag ons bevindinge bydra tot die huidige begrip van die wisselwerking 
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1.1. Introduction 
Progestogens refer to compounds that display progestational activity and include the natural 
hormone progesterone (Prog) as well as progestins (Sitruk-Ware 2004a; Stanczyk et al. 2013). 
Progestins are synthetic compounds that were designed to mimic the effects of Prog (Moore et al. 
2012; Stanczyk et al. 2013), and are used clinically as contraceptives, in hormone replacement 
therapy (HRT) (Sitruk-Ware 2004a; Sitruk-Ware & Nath 2010; Africander, et al. 2011a), for the 
treatment of gynaecological disorders such as endometriosis (Harrison & Barry-Kinsella 2000; 
Irahara et al. 2001; Vercellini et al. 2003) and polycystic ovary syndrome (PCOS) (Archer & Chang 
2004; Guido et al. 2004; Ehrmann 2005; Harwood et al. 2007; Badawy & Elnashar 2011). It should 
be noted that many different progestins have been designed and they are classified into four 
consecutive generations (Stanczyk 2003; Sitruk-Ware 2006). Although these progestins have been 
shown to have many beneficial effects, several side-effects have been associated with their clinical 
use. For example, results from the Women’s Health Initiative (WHI) trial showed that the use of the 
first generation progestin medroxyprogesterone acetate (MPA) in HRT by postmenopausal women, 
increased the risk of developing coronary heart disease (CHD), stroke and breast cancer (Rossouw 
et al. 2002; Chlebowski et al. 2003; Chlebowski et al. 2013a; Chlebowski et al. 2013b), while the 
Million Women Study (MWS) showed an association between using progestins such as MPA, 
norethisterone acetate (NET-A) and levonorgestrel (LNG) in HRT, and increased risk of breast 
cancer (Beral 2003). Similarly, the French E3N cohort study showed that the use of MPA and NET-
A in HRT increased breast cancer risk (Fournier et al. 2005; Fournier et al. 2008). As progestins 
differ in structure, and hence their biological activities (Sitruk-Ware 2006; Sitruk-Ware 2005; 
Sitruk-Ware & Nath 2010), it is possible that not all progestins will elicit the same side-effect 
profile in terms of breast cancer risk. Furthermore, the use of compounded bio-identical hormones 
such as bio-identical Prog (bProg) in HRT has gained popularity as it is claimed to be natural and 
safer in terms of breast cancer risk (Boothby & Doering 2008; Holtorf 2009; Files et al. 2011). 
Considering that breast cancer is the most common cause of cancer death amongst women 
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worldwide (Sommer & Fuqua 2001; Platet et al. 2004; Ferlay et al. 2014), it is of utmost 
importance to understand the mechanisms whereby hormones used in HRT may or may not 
contribute to the development and progression of this disease.  
Progestins, like Prog, mainly elicit their biological effects by binding to the progesterone receptor 
(PR) (Moore et al. 2012; Stanczyk et al. 2013), which is a member of the steroid receptor family 
(Lu et al. 2006; Griekspoor 2007; Africander, et al. 2011a) that exists as two predominant isoforms, 
namely PR-A and PR-B (Kastner et al. 1990; Rękawiecki et al. 2011). Although recent evidence 
suggests that both the PR isoforms may have critical roles in the pathogenesis of hormone-
responsive breast cancers (Daniel et al. 2011; Diep et al. 2015), the exact role of PR-A and PR-B in 
breast cancer development and progression still needs to be elucidated. Furthermore, emerging 
evidence suggest that crosstalk between different steroid receptors may be implicated in breast 
cancer biology. For example, a recent study by Giulianelli and co-workers (2012) showed that the 
estrogen receptor (ER)-α is essential for both PR-A and PR-B mediated effects of MPA on gene 
expression and breast cancer cell proliferation (Giulianelli et al. 2012). Considering that ERα is 
required for PR-mediated activity of MPA (Giulianelli et al. 2012), the question that arises is 
whether ERα is also required for the PR-mediated activity of other progestins. Moreover, as the ER 
exists as two subtypes, ERα and ERβ, another question that comes to mind is whether ERβ is also 
needed for PR-mediated effects of progestins.  
1.2. Progestogens 
1.2.1. Therapeutic applications  
1.2.1.1. Prog and bProg 
The natural progestogen, Prog, is a sex steroid hormone mainly synthesised in the ovaries of the 
female body. Interestingly, Prog is also synthesised de novo from cholesterol in the brain (Tsutsui et 
al. 2000; Hu et al. 2010) through a biosynthetic pathway that is similar to the pathway in the ovaries 
(Hanukoglu 1992; Wickenheisser et al. 2006). Prog plays a very important role in controlling brain 
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functions associated with sexual behaviour and receptivity, as well as in normal female 
development and maintenance of reproductive function in the uterus, ovaries and mammary glands 
(Graham & Clarke 1997; Conneely & Lydon 2000; Toh et al. 2013; Diep et al. 2015). In the uterus 
and ovaries for example, Prog is involved in reproductive processes such as ovulation as well as the 
establishment and maintenance of pregnancy (Conneely & Lydon 2000; Graham & Clarke 2002; 
Diep et al. 2015). It is noteworthy that Prog also elicits anti-proliferative effects in the uterus, so as 
to protect against possible hyperplasia induced by the rise in circulating estrogen levels at the time 
of ovulation during the menstrual cycle (Clarke & Sutherland 1990; Lydon et al. 1995; Conneely et 
al. 2000; Conneely et al. 2002). In contrast, Prog elicits proliferative effects in the normal mammary 
gland, thereby stimulating lobular-alveolar development and expansion to prepare for lactation 
(Lydon et al. 1995; Conneely et al. 2000; Graham & Clarke 2002; Diep et al. 2015). The various 
physiological effects of Prog in different target tissues are primarily mediated by the PR (Conneely 
et al. 2001; Conneely et al. 2003). 
Clinically, Prog has been used either in the form of micronized Prog in conventional HRT (de 
Lignières 2002; Fournier et al. 2005; Fournier et al. 2008) or bProg in bio-identical HRT (bHRT) 
(Ruiz et al. 2011; White 2015). Micronized Prog refers to Prog which has undergone the process of 
micronization whereby the particle size is reduced in order to facilitate increased absorption and 
bioavailability (Maxson & Hargrove 1985; Chakmakjian & Zachariah 1987; Kimzey et al. 1991; 
Norman et al. 1991; Tavaniotou et al. 2000). It is administered either orally, via intramuscular 
injection or vaginally in the form of vaginal creams, suppositories, capsules, pessaries, gels and 
rings (Price et al. 1983; Kimzey et al. 1991; Cicinelli et al. 1996; Fanchin et al. 1997; Tavaniotou et 
al. 2000; Germond et al. 2002; Sitruk-Ware 2007). bProg is synthesized by chemically modifying 
the natural plant product diosgenin (figure 1.1), which can be extracted from plants such as the 
Mexican wild yam and soy (Boothby et al. 2004; Boothby & Doering 2008; Files et al. 2011; 
Bhavnani & Stanczyk 2012), and is reported to have the same chemical structure as natural Prog 
(Boothby et al. 2004; Boothby & Doering 2008; Holtorf 2009; Panay & Fenton 2010; Files et al. 
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2011; Bhavnani & Stanczyk 2012; Guidozzi et al. 2014). Thus, although compounding pharmacies 
claim that bio-identical hormones such as bProg are natural (Boothby et al. 2004), it is in fact semi-
synthetic (Bhavnani & Stanczyk 2012). Compounded bProg can be administered to women either 
orally or vaginally in the form of gels and creams (White 2015). It is noteworthy that a position 
statement by the South African Menopause Society in 2014 indicated that the use of compounded 
bProg may not be as effective in counteracting the proliferative effects of estrogen on the 
endometrium, since bProg produced by compounding pharmacies are not regulated, and thus may 
vary in quality and potency (Guidozzi et al. 2014). Furthermore, claims by these pharmacies that 
bio-identical hormones are safer than the hormones traditionally used in conventional HRT have not 
been substantiated by scientific evidence. Thus, more research is needed to determine the possible 
benefits and risks associated with the use of bio-identical hormones such as bProg in HRT.  
 
 
   
Figure 1.1. The plant product diosgenin is converted to bProg (chemical structure identical to that of 
natural Prog) by multiple chemical reactions. Adapted from Stanczyk et al. (2003). 
 
1.2.1.2. Progestins 
The clinical use of Prog is however restricted due to its rapid metabolism and short half-life 
(Speroff & Darney 1996; Fotherby 1996). In contrast, progestins mostly display greater half-lives 
than Prog (Moore et al. 2012; Stanczyk et al. 2013) and are used in many therapeutic applications, 
most notably for contraception and HRT (Sitruk-Ware 2005a; Sitruk-Ware & Nath 2010; 
Africander, et al. 2011a). A number of different progestins have been designed and are classified 
according to successive generations. The first two generations are considered the older progestins, 
Bio-identical Progesterone (bProg) 
(bProg) 
Diosgenin 
Multiple chemical reactions 
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while the third and fourth generations are regarded as the newer progestins (Sitruk-Ware 2004a; 
Sitruk-Ware & Plu-Bureau 2004; Sitruk-Ware 2005a). Although most progestins are structurally 
related to either Prog or testosterone, the chemical structures of these compounds differ greatly 
from each other and from Prog and testosterone (figure 1.2) (Stanczyk 2003; Sitruk-Ware 2005a; 
Sitruk-Ware 2005b; Sitruk-Ware & Nath 2010). Those progestins derived from Prog are referred to 
as either 17-hydroxyprogesterone or 19-norprogesterone derivatives, while those derived from 
testosterone are referred to as 19-nortestosterone derivatives (Stanczyk 2003; Sitruk-Ware & Nath 
2010). The first generation progestin MPA is an example of a 17-hydroxyprogesterone derivative  
(Sitruk-Ware & Plu-Bureau 2004), while promegestone (R5020) is an example of a 19-
norprogesterone derivative (Schindler et al. 2003; Stanczyk 2003; Sitruk-Ware 2006). Examples of 
19-nortestosterone derivatives include the first generation progestin NET-A or norethisterone 
enanthate (NET-EN), the second generation progestin LNG, and the third generation progestin 
gestodene (GES). It is important to note that NET-A is used in HRT, while NET-EN is used in 
contraception (Schindler et al. 2003; Stanczyk 2003; Sitruk-Ware & Plu-Bureau 2004; Sitruk-Ware 
2006), and that both NET-A and NET-EN are prodrugs which are metabolized to the active 
metabolite NET (Stanczyk & Roy 1990). The fourth and newest generation of progestins include 
drospirenone (DRSP) (Schindler et al. 2003; Stanczyk 2003; Sitruk-Ware & Plu-Bureau 2004; 
Sitruk-Ware 2006), which is unique in that it is derived from the anti-mineralocorticoid 
spironolactone (Krattenmacher 2000; Elger et al. 2003; Oelkers 2004; Sitruk-Ware 2004a; Sitruk-
Ware 2006; Sitruk-Ware 2005). All of the above-mentioned progestins, except R5020, are used in 
both contraception (Lee et al. 1987; Althuis et al. 2003; Li et al. 2012; Wu et al. 2013; Dinger et al. 
2014; Beaber et al. 2014; Stanczyk & Archer 2014; Vinogradova et al. 2015) and HRT (Rossouw et 
al. 2002; Beral 2003; Fournier et al. 2014; Schindler 2014). Notably, R5020 is used in only HRT 
and only in France (de Lignières et al. 2002; Fournier et al. 2005; Fournier et al. 2008). However, it 
is extensively used as an experimental tool to investigate PR-specific effects (Chwalisz et al. 2006).  
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For contraception, progestins are administered to women either alone, or in combination with 
estrogens for enhanced cycle control (Sitruk-Ware 2005b; Sitruk-Ware & Nath 2010; Africander, et 
al. 2011a). Progestin-only contraceptives can be taken either orally or be administered as an 
injection, or in subcutaneous implants, vaginal rings and intrauterine devices, while estrogen-
progestin combined contraceptives are administered either orally or in vaginal rings and 
contraceptive patches (Brache et al. 2000; Kahn et al. 2003; Erkkola & Landgren 2005; Sitruk-Ware 
2006; Black & Kubba 2008; Nath & Sitruk-Ware 2009; Rakhi & Sumathi 2011; Brache et al. 2013; 
Sitruk-Ware et al. 2013; Jacobstein & Polis 2014). Interestingly, progestins are also being 
investigated for its possible use in male contraception (Gu et al. 2004; Ilani et al. 2012; Kanakis & 
Goulis 2015; Roth et al. 2015; Wang et al. 2016). Several studies have shown that combining 
progestins with testosterone suppresses spermatogenesis due to the progestin and testosterone 
synergistically suppressing gonadotropin hormone levels (Kamischke, et al. 2000a; Kamischke, et 
al. 2000b; Nieschlag et al. 2003; Gu et al. 2004; Amory 2008; Ilani et al. 2012; Costantino et al. 
2014; Chao & Page 2016). In terms of HRT, estrogen combined with a progestin is commonly 
prescribed to menopausal women with an intact uterus. The estrogen is given to alleviate symptoms 
associated with decreasing levels of estrogen (Greendale et al. 1999; Hickey et al. 2005; Africander, 
et al. 2011a) such as hot flashes, night sweats and vaginal dryness (Greendale et al. 1999; Hickey et 
al. 2005), while a progestin is added to protect against endometrial cancer caused by the 
proliferative effects of estrogen on the endometrium (Whitehead et al. 1979; Greendale et al. 1999; 
Hickey et al. 2005). HRT regimens are administered either orally, via transdermal patches, gels or 
vaginal rings (Nath & Sitruk-Ware 2009; Hickey et al. 2012; Stanczyk et al. 2013).  
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Figure 1.2. Chemical structures of select progestogens. The chemical structures for (A) promegestone 
(R5020) and (B) natural progesterone (Prog), as well as the progestins (C) medroxyprogesterone acetate 
(MPA), (D) norethisterone (NET), (E) levonorgestrel (LNG), (F) gestodene (GES) and (G) drospirenone 
(DRSP) are illustrated. Adapted from Louw-du Toit et al. (2016).  
 
Other therapeutic applications of progestins include treatment of gynaecological disorders such as 
dysmenorrhea (painful menstruation), menorrhagia (heavy menstrual bleeding) (Williams & 
Creighton 2012), endometriosis (a disease that leads to pelvic pain and infertility) (Harrison & 
Barry-Kinsella 2000; Irahara et al. 2001; Vercellini et al. 2003) and PCOS (Archer & Chang 2004; 
Guido et al. 2004; Ehrmann 2005; Harwood et al. 2007; Setji & Brown 2007; Badawy & Elnashar 
2011). PCOS is a endocrine disorder causing symptoms such as irregular ovulation (oligo-
ovulation) or a complete lack of ovulation (anovulation), elevated levels of androgens and 
infertility, as well as complications such as insulin resistance and diabetes  (Archer & Chang 2004; 
Guido et al. 2004; Ehrmann 2005; Harwood et al. 2007; Setji & Brown 2007; Badawy & Elnashar 
2011). Interestingly, high dosages of progestins such as  MPA (500 and 1500 mg/day [Blossey et al. 
1984]) have also been used  for the treatment of breast (Lundgren 1992; Yamashita et al. 1996; 
Cardoso et al. 2012; Cardoso et al. 2013) and endometrial cancer (Lentz et al. 1996; Thigpen & 
Brady 1999; Kim et al. 2013). Despite the number of beneficial effects associated with the 
therapeutic use of progestins, a number of side-effects have been reported for some progestins 
(Mostad et al. 2000; Kass-Wolff 2001; Rossouw et al. 2002; Anderson et al. 2003; Cromer et al. 
2004; Morrison et al. 2004; Sitruk-Ware 2004b; Sitruk-Ware 2006; Ojule et al. 2010; Morrison et 
al. 2010). 
1.2.2. Side-effects  
To the best of our knowledge, no major side-effects have been reported with the clinical use of Prog 
and bProg, while a number of side-effects have been associated with the clinical use of some 
progestins. Some of the less severe side-effects include bloating, weight gain, headaches, nausea, 
fatigue, depression, insomnia, abdominal pain, reduced libido, vaginal itchiness, breast tenderness, 
mood changes, amenorrhea and irregular bleeding (Li et al. 2000; Greydanus et al. 2001; Sitruk-
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Ware 2004b; Erkkola & Landgren 2005; Sitruk-Ware 2006; Ojule et al. 2010; Moore et al. 2012; 
Williams & Creighton 2012). More severe side-effects include changes in lipid and lipoprotein 
levels in postmenopausal women using progestins like MPA and NET-A in HRT, which in turn 
could increase cardiovascular risk (Sitruk-Ware 2000). In addition, progestins such as MPA, NET, 
LNG, GES and DRSP used in both contraception and HRT have been shown to increase the risk of 
venous thromboembolism (VTE) and stroke in a number of independent studies (Rossouw et al. 
2002; Warren 2004; Lidegaard et al. 2012; Manzoli et al. 2012; Sidney et al. 2013; Wu et al. 2013; 
Dinger et al. 2014; Vinogradova et al. 2015). Furthermore, several studies have shown that the use 
of the injectable contraceptive depot-MPA (DMPA) by adolescent females is associated with 
decreased bone mineral density (Kass-Wolff 2001; Cromer et al. 2004; Lara-Torre et al. 2004; 
Williams & Creighton 2012), a condition which is reversed when the use of this contraceptive is 
discontinued (Cundy et al. 1994). Interestingly, postmenopausal women using combined HRT 
formulations containing MPA have been shown to be at an increased risk of dementia (Rossouw et 
al. 2002; Warren 2004). Alarmingly, the contraceptive use of MPA has also been shown to 
modulate the local immune response in the female genital tract, thereby increasing susceptibility to 
genital tract infection such as herpes simplex virus type (HSV)-2 (Mostad et al. 2000), chlamydia 
(Morrison et al. 2004), gonorrhoea (Morrison et al. 2004) and human immunodeficiency virus 
(HIV)-1 (Morrison et al. 2010). Although MPA can be used for the treatment of breast and 
endometrial cancer, evidence in the literature suggests that MPA may in fact be associated with 
increased risk of developing breast (Lee et al. 1987; Riis et al. 2002; Rossouw et al. 2002; Beral 
2003; Althuis et al. 2003; Stahlberg et al. 2003; Li et al. 2012; Beaber et al. 2014), as well as 
ovarian cancer (Anderson et al. 2003). For example, the use of MPA, NET and LNG in 
contraception (Lee et al. 1987; Althuis et al. 2003; Li et al. 2012; Beaber et al. 2014) and HRT (Riis 
et al. 2002; Rossouw et al. 2002; Beral 2003; Stahlberg et al. 2003) have all been associated with 
increased risk of breast cancer.  
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Many of the undesirable side-effects observed with the clinical use of progestins are thought to be 
due to the cross-reactivity of progestins with steroid receptors other than the PR. For example, 
bloating, weight gain, as well as salt and water retention is associated with progestins lacking anti-
mineralocorticoid activity (Li et al. 2000; Greydanus et al. 2001; Elger et al. 2003; Sitruk-Ware 
2006; Ojule et al. 2010; Moore et al. 2012; Stanczyk et al. 2013), whereas interference with the 
local immune response in the female genital tract  and decreased bone mineral density, may be 
attributed to the glucocorticoid-like properties of progestins such as MPA (Ishida et al. 2002; Ishida 
et al. 2008; Tomasicchio et al. 2013; Louw-du Toit et al. 2014). However, despite the ability of 
some progestins to exert off-target biological effects via other steroid receptors, the actions of 
progestins via the PR itself have also been implicated in side-effects such as increased risk of breast 
cancer. For example, results from a study by Wargon et al. (2014) showed that the stimulatory 
effects of MPA on breast tumour growth were mediated by the PR. Details of the PR structure and 
general mechanism, as well as the cellular mechanism of action of progestins via the PR, will be 
discussed in Section 1.3. 
1.3. Structure and general mechanism of the progesterone receptor (PR) 
1.3.1. Structure 
The PR is a steroid receptor which belongs to the nuclear receptor superfamily, comprising the PR, 
androgen receptor (AR), mineralocorticoid receptor (MR), glucocorticoid receptor (GR) and ER 
(Lu et al. 2006; Griekspoor 2007). These receptors are ligand-activated transcription factors that 
share similar structures and mechanisms of action (Griekspoor 2007; Africander, et al. 2011a). In 
females, the PR is expressed in various target tissues including the uterus, ovary, mammary gland, 
brain, pituitary gland and the pancreas (Graham & Clarke 1997; Africander, et al. 2011a). The PR, 
like other steroid receptors, consists of the following functional domains: a highly variable amino-
terminal domain, a central highly conserved DNA binding domain (DBD), a flexible hinge region 
and a carboxy-terminal domain containing a moderately conserved ligand binding domain (LBD) 
(figure 1.3) (Kastner et al. 1990; Giangrande et al. 1997; Scarpin et al. 2009; Rękawiecki et al. 
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2011). The amino-terminal domain contains a ligand-independent activation function (AF)-1 
domain which is important for optimal transcriptional activity and is responsible for protein-protein 
interactions with transcription factors and co-factors (Giangrande et al. 1997; Rękawiecki et al. 
2011). The DBD allows binding of the receptor to target DNA sequences, dimerization of the 
receptor and interactions with certain co-factors involved in transcription, while the LBD is 
responsible for ligand-binding (Giangrande et al. 1997; Rękawiecki et al. 2011). The LBD contains 
a ligand-dependent AF-2 domain, and the LXXLL motif found within this domain is involved in 
protein-protein interactions with transcription factors and chaperone proteins (Scarpin et al. 2009; 
Rękawiecki et al. 2011; Jacobsen & Horwitz 2012). Moreover, both the DBD and LBD are essential 
for nuclear translocation of the steroid receptor-hormone complex (Griekspoor 2007).  
Figure 1.3. A schematic illustration of the structural and functional domains of the PR isoforms. The 
PR consists of the following domains: an amino-terminal domain (A/B), the DNA binding domain (DBD; 
C), the flexible hinge region (D) and the carboxy-terminal domain containing the ligand binding domain 
(LBD; E). PR-A has a truncated version of the A/B domain (lacking AF-3), whilst PR-C has a truncated C 
domain and lacks the A/B domain. AF - activation function; IF - inhibitory function. Adapted from 
Rękawiecki et al. (2011) and Africander et al. (2011a). 
 
Three distinct PR isoforms exist namely PR-A, PR-B and PR-C (figure 1.3) (Kastner et al. 1990; 
Wei & Gonzalez-Aller 1990; Daniel et al. 2011; Rękawiecki et al. 2011), which are transcribed 
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from three different promoters of a single gene (Kastner et al. 1990; Wei & Gonzalez-Aller 1990; 
Rękawiecki et al. 2011). PR-A is a 94 kDa protein, while PR-B (~110 kDa) is larger as it contains 
an additional 164 amino acids at the amino-terminal (Kastner et al. 1990; Giangrande et al. 1997; 
Giangrande et al. 2000). An AF-3 domain is found in this amino-terminal region (Kastner et al. 
1990; Giangrande et al. 1997; Rękawiecki et al. 2011),  which leads to the binding of certain co-
activators to PR-B, but not PR-A (Giangrande et al. 2000; Graham & Clarke 2002; Tung et al. 
2006). Furthermore, both PR-A and PR-B contain an inhibitory function (IF) domain in their 
amino-terminal domains which have been shown to interact with co-repressors (Giangrande et al. 
1997; Rękawiecki et al. 2011; Jacobsen & Horwitz 2012). In contrast to PR-A and PR-B, PR-C is a 
small 60 kDa protein that lacks the entire amino-terminal domain as well as a large part of the DBD 
(Wei & Gonzalez-Aller 1990; Daniel et al. 2011). PR-C thus cannot bind DNA and is 
transcriptionally inactive (Daniel et al. 2011; Rękawiecki et al. 2011; Abdel-Hafiz & Horwitz 
2014). 
The evidence in the literature suggests that PR-A and PR-B may display differential physiological 
functions in different target tissues. For example, PR-B is more proliferative in the breast as it is 
mainly involved in mammary gland branching and alveologenesis (Conneely et al. 2003), whereas 
PR-A is more proliferative in the uterus as it plays an important role in the development of the 
uterus and implantation of the fertilized ovum (Conneely et al. 2001; Mulac-Jericevic & Conneely 
2004; Diep et al. 2015). It is well-known that PR-A is a repressor of PR-B activity (Vegeto & 
Shahbaz 1993), as well as that of the ER, AR, MR and GR (McDonnell & Goldman 1994; 
McDonnell et al. 1994; Kraus et al. 1995; Kraus et al. 1997; Conneely & Lydon 2000). As PR-B 
has been reported to be more transcriptionally active than PR-A in the presence of ligand (Kastner 
et al. 1990; Edwards et al. 1995; Rękawiecki et al. 2011; Jacobsen & Horwitz 2012), we mainly 
focussed on the activity of PR-B in this thesis. 
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1.3.2. Mechanisms of action 
Unliganded PR-B is evenly distributed between the cytoplasm and the nucleus (Lim et al. 1999; Li 
2005; Griekspoor 2007), and is associated with chaperone proteins such as heat shock protein 
(hsp)90 and hsp70, p23 and immunophillins (Griekspoor 2007; Rękawiecki et al. 2011). In the 
presence of ligand, PR-B undergoes a conformational change which ultimately leads to the 
dissociation of the multiprotein complex, leading to the activation of signalling pathways through 
either non-genomic (Boonyaratanakornkit et al. 2001; Boonyaratanakornkit et al. 2007; Carnevale 
et al. 2007; Boonyaratanakornkit et al. 2008; Kariagina et al. 2008) or genomic mechanisms 
(Rękawiecki et al. 2011). Non-genomic mechanisms involves rapid signalling pathways and include 
a direct interaction of cytoplasmic ligand-bound PR-B with the membrane-associated c-Src tyrosine 
kinase (Boonyaratanakornkit et al. 2001; Boonyaratanakornkit et al. 2007; Carnevale et al. 2007; 
Boonyaratanakornkit et al. 2008; Kariagina et al. 2008), while genomic mechanisms can take hours 
and involves the translocation of ligand-bound PR-B to the nucleus where it regulates gene 
expression (Griekspoor 2007; Africander, et al. 2011a; Rękawiecki et al. 2011). It is important to 
note that ligand-induced non-genomic mechanisms can also occur via a membrane PR (mPR) 
(Thomas et al. 2007; Thomas 2008; Stanczyk et al. 2013) 
1.3.2.1. Non-genomic mechanisms 
PR-B contains a proline-rich PXXPXR motif in its amino-terminal domain enabling the 
cytoplasmic ligand-bound PR-B to directly bind to the Src-homology (SH-3) domain of c-Src 
(Boonyaratanakornkit et al. 2001; Carnevale et al. 2007). This results in activation of either the c-
Src/Ras/mitogen-activated protein kinase (MAPK) or phosphatidylinositol 3-kinase (PI3K)/Akt 
signalling pathways (Boonyaratanakornkit et al. 2007). Activation of these signalling pathways 
ultimately leads to the activation of other transcription factors via phosphorylation events (Saitoh et 
al. 2005; Carnevale et al. 2007; Boonyaratanakornkit et al. 2008). For example, the transcription 
factors activator protein-1 (AP-1) and nuclear factor kappa B (NFκB) have been shown to be 
activated by phosphorylation when the MAPK and PI3K/Akt signalling pathways are activated 
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(Faivre et al. 2005; Saitoh et al. 2005). It has been suggested that this mechanism allows PR-B to 
activate transcription of genes that do not contain progesterone response elements (PREs) in their 
promoter regions, such as the PR-B-mediated upregulation of cyclin D1 by MPA (Saitoh et al. 
2005).  
Non-genomic mechanisms can also be mediated via binding of a progestogen to an mPR, which has 
been shown to be a part of the progestin and adiponectin Q receptor family (PAQR) (Tang et al. 
2005; Thomas et al. 2007; Thomas 2008; Dressing et al. 2011). Similarly to a G protein-coupled 
receptor (GPCR), the PAQR contains a seven transmembrane domain and can couple and activate 
G-proteins (Tang et al. 2005; Thomas et al. 2007; Thomas 2008; Gellersen et al. 2009; Dressing et 
al. 2011). Interestingly, phylogenetic analysis has revealed that PAQRs have a different ancestral 
origin than GPCRs (Tang et al. 2005; Thomas et al. 2007; Thomas 2008; Dressing et al. 2011). 
Following the binding of a PR ligand to mPR and the activation of G-proteins, downstream MAPK 
and/or PI3K/Akt signalling pathways are activated, leading to the subsequent phosphorylation and 
activation of nuclear proteins, which include other transcription factors (Edwards 2005; Stanczyk et 
al. 2013).  
1.3.2.2. Genomic mechanisms 
Genomic mechanisms of PR-B refers to the transcriptional regulation of target genes either 
positively (transactivation) or negatively (transrepression) (Griekspoor 2007; Africander, et al. 
2011a; Rękawiecki et al. 2011). The ligand-bound PR-B binds as a dimer to PREs located in the 
promoter regions of PR regulated genes (figure 1.5) (Bagchi et al. 1988; Giangrande et al. 1997; 
Rękawiecki et al. 2011). Components of the basal transcription machinery and other necessary co-
regulatory proteins such as co-activators as well as chromatin remodelling proteins are subsequently 
recruited to the promoters of the target genes (Beato & Klug 2000; Griekspoor 2007; Africander, et 
al. 2011a; Rękawiecki et al. 2011). Histones are then acetylated which leads to chromatin 
decondensation (McKenna et al. 1999), and the subsequent activation of transcription in a process 
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called transactivation (Beato & Klug 2000; Griekspoor 2007; Africander, et al. 2011a; Rękawiecki 
et al. 2011).  
 
Figure 1.4. An illustration of the non-genomic mechanisms of action of progestogens via intracellular 
PR-B and the membrane-bound PR (mPR). PR ligands such as Prog or progestins can elicit biological 
effects through non-genomic signalling mechanisms by either binding to intracellular PR-B or the mPR. For 
the rapid activation of intracellular PR-B, the ligand diffuses across the cell membrane and binds to 
cytoplasmic PR-B, followed by the dissociation of heat-shock proteins, immunophillins and other chaperone 
proteins from PR-B. The ligand-bound PR-B binds and subsequently activates c-Src, which leads to the 
activation of the MAPK and/or PI3K/Akt signalling pathways. For activation of mPR, the ligand binds to 
mPR which in turn activates kinases such as MAPK and/or PI3K/Akt. Finally, these signalling cascades 
activate other transcription factors through phosphorylation, and lead to the regulation of genes without a 
progesterone response element (PRE) sequence. Adapted from Giulianelli et al. (2012) and Stanczyk et al. 
(2013). 
 
PR-B can  negatively regulate transcription (Rękawiecki et al. 2011; Abdel-Hafiz & Horwitz 2014) 
when the ligand-activated PR-B represses the activity of the transcription factor NFκB (Kalkhoven 
et al. 1996; Kobayashi et al. 2010) via an interaction between the PR and the p65-subunit of NFκB. 
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Co-repressors and chromatin remodelling proteins are subsequently recruited to the promoter 
regions of the target genes (Daniel et al. 2009; Africander et al. 2011a), and transcription is 
inhibited as a result of condensed chromatin due to histone deacetylation (McKenna et al. 1999; 
Gronemeyer et al. 2004; Rękawiecki et al. 2011). This negative regulation of target gene expression 
is referred to as transrepression (figure 1.5) (Kalkhoven et al. 1996).  
  
Figure 1.5. An illustration of the genomic mechanisms of PR-B. The ligand (e.g. Prog or progestin) 
diffuses across the cell membrane and binds to the intracellular PR-B. The receptor undergoes a 
conformational change allowing the dissociation of heat-shock proteins, immunophillins and other chaperone 
proteins. The activated PR-B then translocates to the nucleus where it either activates transcription of target 
genes by binding as a dimer to PREs (transactivation) or represses transcription of target genes due to the PR 
monomer tethering to a DNA-bound transcription factor such as NFκB (transrepression). Adapted from 
Africander et al. (2011a). 
 
1.4. The PR, progestins and breast cancer 
For many years, the role of the PR in breast cancer was thought to be limited to only a prognostic 
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development and progression of breast cancer (Horwitz & McGuire 1978; Hefti et al. 2013). 
However, recent evidence suggest that the PR itself can directly contribute to the development of 
breast cancer by upregulating the expression of genes known to be involved in the development and 
progression of breast cancer (Giulianelli et al. 2012; Wargon et al. 2014). Whilst PR-A and PR-B 
are present at equimolar concentrations in the normal breast (Mote et al. 2002), PR-A is often 
overexpressed in breast cancer (Graham et al. 1995; Bamberger et al. 2000; Ariga et al. 2001; Hopp 
et al. 2004). In fact, studies have shown that the ratio of the PR isoforms, PR-A:PR-B, is an 
important determinant of breast cancer development and progression (Graham et al. 1995; Mote et 
al. 2002; Hopp et al. 2004; Cui 2005). For example, breast tumours expressing high PR-A:PR-B 
ratios have been shown to be more aggressive and pose a higher risk of relapse (Hopp et al. 2004). 
Although the exact cause for the altered PR-A:PR-B ratio in breast cancer has not been fully 
elucidated, it has been suggested that it may be due to an increase in the activity of kinases such as 
MAPK in breast cancers (Daniel et al. 2007; Diep et al. 2015). This increased kinase activity leads 
to increased phosphorylation of PR-B, which in turn leads to hyperactivation and an increase in the 
rate of PR-B protein turnover (Daniel et al. 2011; Diep et al. 2015).  
Breast cancer is one of the most commonly diagnosed cancers (Platet et al. 2004), and the most 
common cause of cancer death amongst women worldwide (Sommer & Fuqua 2001; Ferlay et al. 
2014). Understanding factors which may contribute to the development of this disease, such as the 
PR and the activity of ligands binding to the receptor, is therefore essential. Although a number of 
studies have started investigating the role of the PR in breast cancer (Hyder et al. 1998; Hyder et al. 
2001; Moore et al. 2006; Jacobsen et al. 2003; Mueller et al. 2003; Sartorius et al. 2003; Wu et al. 
2004; Liang et al. 2007; Giulianelli et al. 2012; Bellance et al. 2013; Kariagina et al. 2013; Wargon 
et al. 2014; Diep et al. 2015), and examined whether PR ligands (progestogens) increase the risk of 
developing breast cancer (Rossouw et al. 2002; Beral 2003; Anderson et al. 2004; Li et al. 2012), 
results are often contradictory and many questions remain unanswered. In the next section, the 
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existing knowledge on the PR and progestogens in breast cancer development and progression will 
be reviewed. 
1.4.1. Clinical and epidemiological studies 
Concerns that progestins increase breast cancer risk were raised by the results of the Women’s 
Health Initiative (WHI), a large-scale randomised clinical trial (Rossouw et al. 2002). This study 
examined the health benefits and risks associated with the use of HRT, either administered as 
conjugated equine estrogen (CEE) alone or as an estrogen-progestin combination (CEE–MPA) 
(Rossouw et al. 2002; Anderson et al. 2004). The estrogen-progestin combined HRT treatment 
component of the trial was stopped earlier than planned due to an increase in the risk of developing 
several adverse conditions such as CHD, stroke, pulmonary embolism and most relevant to this 
thesis, invasive breast cancer (Rossouw et al. 2002; Chlebowski et al. 2003; Chlebowski et al. 
2013a; Chlebowski et al. 2013b). Notably, the estrogen only trial was stopped two years later due to 
an increased risk of stroke, but no significant effect on CHD or breast cancer risk was observed 
(Anderson et al. 2004). These results suggest that the MPA component was responsible for the 
increased CHD and breast cancer risk in the estrogen-progestin arm of the trial. Evidence from 
observational studies also indicate an association between HRT and increased risk of breast cancer 
(Ross et al. 2000; Newcomb et al. 2002). For example, results from an observational study two 
years prior to the publication of the WHI results showed that the use of CEE alone, as well as the 
use of estrogen-progestin HRT (CEE-MPA) was associated with increased risk of breast cancer in 
postmenopausal women, with a higher risk associated with the CEE-MPA HRT (Ross et al. 2000). 
Similarly, a population-based case-control study by Newcomb et al. (2002) also showed that CEE-
MPA therapy was associated with a greater breast cancer risk in postmenopausal women 
(Newcomb et al. 2002). In agreement with the above-mentioned studies, results from the Million 
Women Study found that both estrogen only HRT and combined HRT preparations containing 
MPA increased the risk of developing breast cancer in long-term HRT users (Beral 2003). 
However, this study examined the effects of different types of progestins and estrogens on breast 
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cancer incidence and mortality in over one million HRT users,  and found that even though 
combined estrogen-progestin formulations were associated with a greater breast cancer risk than 
estrogen only formulations, there were no significant differences in terms of risk between the 
different estrogens or progestins (Beral 2003). The estrogens examined were CEE and ethinyl 
estradiol (EE), while the progestins examined were the first generation progestins MPA and NET-
A, as well as the second generation progestin LNG. This higher breast cancer risk associated with 
different estrogen-progestin formulations was also observed in the French E3N cohort study 
evaluating the risk of breast cancer associated with the use of MPA- and NET-A-containing 
combined HRT formulations and estrogen-only HRT formulations in post-menopausal women 
(Fournier et al. 2005; Fournier et al. 2008). Interestingly, this same study also showed that estrogen-
progestin combined formulations containing the synthetic progestin R5020, considered to be PR-
specific, significantly increased breast cancer risk (Fournier et al. 2005; Fournier et al. 2008). 
Studies have shown that, in contrast to HRT formulations containing the above-mentioned 
estrogens and progestins, formulations containing estrogenic compounds such as estradiol (E2) and 
CEE in combination with micronized Prog, did not affect breast cancer risk (de Lignières et al. 
2002; Fournier et al. 2005; Fournier et al. 2008). Similarly, no incidence of breast cancer was 
reported  with the use of compounded bProg either alone or in combination with E2 as part of bio-
identical HRT preparations, (Ruiz et al. 2011). In agreement with this, a recent study on breast 
cancer risk in 101 women administered a combined HRT regimen of compounded bProg in 
combination with biest (combination of E2 and estriol (E3), reported no incidence of breast cancer in 
any of the women tested over a four year period (White 2015). Although these results may be 
promising, much larger randomised control studies on the use of bProg over longer periods are, 
however, needed to definitively prove that the use of bProg in HRT is “safer” than the use of 
progestins in terms of breast cancer risk.  
Most studies investigating effects of progestins on breast cancer, focus on the association of breast 
cancer risk in postmenopausal women using HRT. However, some studies have also investigated 
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the association between the contraceptive use of progestins and increased breast cancer risk (Lee et 
al. 1987; Althuis et al. 2003; Hunter et al. 2010; Li et al. 2012; Beaber et al. 2014), with the results 
often contradictory. For example, two studies  have shown that the injectable progestin-only 
contraceptive DMPA enhanced breast cancer risk (~2.2 to 2.6-fold) in women aged 20 to 58 (Lee et 
al. 1987; Li et al. 2012), while two other studies showed no effect on breast cancer risk (Paul et al. 
1989; Shapiro et al. 2000). Interestingly, the use of combined oral contraceptive (COC) 
formulations containing either NET or LNG has also been shown to increase breast cancer risk 
(Althuis et al. 2003). Similarly, Hunter et al. (2010) reported an increase in breast cancer risk with 
the use of triphasic  LNG-containing COCs when compared to women not using oral contraception 
(Hunter et al. 2010). Triphasic COCs refer to contraceptive formulations that are given in three 
stages and each stage contains different concentrations of estrogens and progestins. In contrast to 
Althuis et al. (2003), Hunter and co-workers (2010) reported no increase in breast cancer risk with 
the use of NET-containing COCs (Hunter et al. 2010). It is noteworthy that a recent population-
based case-control study by Beaber et al. (2014) showed that COC formulations containing either 
NET, LNG or DRSP, increased the risk of breast cancer to similar extents (Beaber et al. 2014). 
Collectively, these results suggest that the first- (MPA and NET-A), second- (LNG) and fourth 
(DRSP) generation progestins all increase the risk of breast cancer. However, considering that a 
large number of progestins are available for clinical use and that progestins are structurally different 
(Stanczyk 2003; Sitruk-Ware 2004a), it may be possible that not all progestins would cause an 
increase in breast cancer risk. 
1.4.2. Experimental studies 
Various processes are implicated in the development and progression of breast cancer, including 
continual proliferation, evasion of apoptosis, sustained angiogenesis as well as migration and 
invasion of breast cancer cells (Hanahan & Weinberg 2000; Sledge & Miller 2003; Hanahan & 
Weinberg 2011). In the next sections, the effects of progestogens and/or the PR on these processes 
will be reviewed.  
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1.4.2.1. Proliferation 
Proliferation is an important process for cell growth and renewal, maintaining tissue homeostasis 
and normal cellular function (Hall & Levison 1990; Sears & Nevins 2002; DeBerardinis et al. 2008; 
Hanahan & Weinberg 2011). In normal cells, this process is under tight regulation of the cell cycle 
(Vermeulen et al. 2003; DeBerardinis et al. 2008), while this process becomes dysregulated in 
cancer allowing the uncontrolled proliferation of cells to continue (Vermeulen et al. 2003; Hanahan 
& Weinberg 2011). A number of studies have investigated the effects of progestogens (Horwitz & 
Freidenberg 1985; van der Burg et al. 1992; Catherino et al. 1993; Botella et al. 1994; Kalkhoven et 
al. 1994; Krämer et al. 2006; Ruan et al. 2012) and the role of the ligand-bound PR (Giulianelli et 
al. 2012; Wargon et al. 2014) on breast cancer cell proliferation. Findings from several in vitro 
studies investigating the effects of progestins on proliferation of normal and cancerous breast 
epithelial cell lines are contradictory, with the effects appearing to be cell line dependent (Horwitz 
& Freidenberg 1985; van der Burg et al. 1992; Catherino et al. 1993; Botella et al. 1994; Kalkhoven 
et al. 1994; Krämer et al. 2006; Ruan et al. 2012). For example, NET, LNG and GES were shown to 
cause proliferation of the human HCC1500 and MCF-7 breast cancer cell lines (van der Burg et al. 
1992; Catherino et al. 1993; Kalkhoven et al. 1994; Krämer et al. 2006; Ruan et al. 2012), while 
having no effect on the normal human breast epithelial cell line MCF10A (Krämer et al. 2006). 
Interestingly, the newer generation progestin, DRSP, also displayed a proliferative effect on the 
MCF-7 breast cancer cell line (Ruan et al. 2012). GES has also been shown to have proliferative 
effects in the T47D breast cancer cell line, while NET and R5020 have been shown to inhibit 
proliferation of the T47D cells (Horwitz & Freidenberg 1985; Botella et al. 1994; Kalkhoven et al. 
1994). In contrast to NET, LNG and GES, MPA has been shown to stimulate proliferation of the 
normal MCF-10A breast cell line (Krämer et al. 2006), while inhibiting proliferation of the 
HCC1500 and T47D breast cancer cell lines (Botella et al. 1994; Krämer et al. 2006), and having no 
significant effect on the proliferation of the MCF-7 breast cancer cells (Catherino et al. 1993; Ruan 
et al. 2012). Two other studies, however, have shown that MPA stimulates T47D breast cancer cell 
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proliferation (Liang et al. 2006), and that the PR antagonist mifepristone (RU486) was able to 
inhibit this effect (Giulianelli et al. 2012; Wargon et al. 2014). These authors thus suggested that the 
PR mediates the proliferative effect of MPA. However, this result should be carefully interpreted as 
RU486 is not only a PR antagonist, but also an AR and a GR antagonist, both of which are 
expressed in T47D cells (Spitz & Bardin 1993; Song et al. 2004). Wargon and co-workers (2014) 
provided more convincing data for a role of the PR when showing that MPA-induced T47D breast 
cancer cell proliferation is abolished once PR-B expression is silenced (Wargon et al. 2014).  
Prog has been shown to have no effect on the growth of normal MCF-10A breast cells, or the 
HCC1500 and MCF-7 breast cancer cells (Krämer et al. 2006; Ruan et al. 2012). In contrast, Wiebe 
and co-workers (2000) showed that Prog has an anti-proliferative effect on both the normal MCF-
10A breast cells and the MCF-7 breast cancer cells (Wiebe et al. 2000). Similarly, Prog has also 
been shown to inhibit proliferation of MDA-MB-231 breast cancer cells co-transfected with PR-A 
and PR-B (Lin et al. 1999), as well as T47D breast cancer cells endogenously expressing both PR-A 
and PR-B (Formby & Wiley 1998). Conversely, Liang and co-workers (2006) showed that Prog has 
pro-proliferative effects on T47D cells, as well as BT-474 breast cancer cells (Liang et al. 2006). To 
the best of our knowledge, the effect of bProg on breast cancer cell proliferation has not been 
investigated.  
Progestins have been shown to regulate the expression of genes which play important roles in breast 
cancer cell proliferation (Wong & Murphy 1991; Moore et al. 1997; Thuneke et al. 2000; 
Giulianelli et al. 2012; Wargon et al. 2014). For example, R5020 (Moore et al. 1997) and MPA 
(Wong & Murphy 1991; Giulianelli et al. 2012; Wargon et al. 2014) have been shown to upregulate 
c-myc mRNA expression in T47D breast cancer cells. The c-myc gene is a marker for proliferation 
which has been shown to be overexpressed in breast cancer (Moore et al. 1997). Considering that 
the c-myc proto-oncogene contains a PRE sequence in its promoter, it has been suggested that the 
upregulation of this gene, at least for R5020, is mediated by the PR binding to PRE (Moore et al. 
1997). MPA has also been shown to upregulate the mRNA (Giulianelli et al. 2012; Wargon et al. 
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2014) and protein expression of another well-known marker of proliferation, Cyclin D1 in T47D 
cells (Thuneke et al. 2000). Interestingly, chromatin immunoprecipitation (ChIP) assays showed 
that the PR is recruited to both the c-myc and Cyclin D1 gene promoters upon treatment with MPA, 
suggesting that the PR is involved in the MPA-induced upregulation of these genes (Giulianelli et 
al. 2012; Wargon et al. 2014). Surprisingly, information on the effects of Prog on c-myc and Cyclin 
D1 mRNA expression is not readily available. 
1.4.2.2. Apoptosis 
Apoptosis, also known as programmed cell death, is a naturally occurring process which plays an 
important role in normal cell turnover and the elimination of improperly developed and damaged 
cells (Thompson 1995; Elmore 2007). In cancer, however, apoptosis is often evaded (Thompson 
1995; Hanahan & Weinberg 2000; Hanahan & Weinberg 2011) To date, a number of studies have 
investigated the effects of progestins and the role of the PR on apoptosis. For example, R5020 
(Moore et al. 2006) and MPA (Ory et al. 2001; Franke & Vermes 2003) have been shown to display 
anti-apoptotic effects on the T47D and MCF-7 cell lines, while MPA has also been shown to inhibit 
apoptosis of the H466B breast cancer cell line (Ory et al. 2001). Similarly, NET-A (Franke & 
Vermes 2003) and R5020 (Moore et al. 2006) inhibited apoptosis of the MCF-7 and MDA-MB-231 
breast cancer cells, respectively. Moreover, Moore et al. (2006) showed that the anti-apoptotic 
effect of R5020 in the T47D cell line is at least partly mediated via the PR, as the PR, GR and AR 
antagonist, RU486, was able to partially abrogate the R5020-induced effect (Moore et al. 2006). In 
contrast to the progestins that all appear to inhibit apoptosis, evidence from the literature regarding 
the effects of Prog on cell death is contradictory. For example, Moore and co-workers showed that 
100 nM Prog inhibits apoptosis of T47D breast cancer cells (Moore et al. 2006), while other studies 
have shown that 10 µM Prog exhibits pro-apoptotic effects in both the T47D (Formby & Wiley 
1998; Formby & Wiley 1999) and MCF-7 breast cancer cells (Franke & Vermes 2003), suggesting 
concentration-specific effects. 
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The process of apoptosis is dependent on a balance between the expression of pro-apoptotic and 
anti-apoptotic genes (Ory et al. 2001). Studies investigating the effects of progestins on the 
expression of pro-apoptotic and anti-apoptotic genes are limited. Findings from one study showed 
that R5020 downregulated the mRNA expression of the pro-apoptotic tumor-suppressor p53 gene in 
T47D cells, suggesting that R5020 is anti-apoptotic (Hurd et al. 1995). In contrast, Moore et al. 
(2000) showed that R5020 downregulated the expression of the anti-apoptotic bcl-2 gene, 
suggesting that R5020 promotes apoptosis (Moore et al. 2000). The first generation progestin, MPA 
has been shown to upregulate the mRNA expression of the pro-apoptotic bcl-xS gene and 
downregulate bcl-2 mRNA expression in T47D cells, suggesting that MPA is pro-apoptotic (Ory et 
al. 2001). However, this same study also reported that MPA upregulated the mRNA expression of 
the anti-apoptotic bcl-xL gene in T47D cells, while having no effect on the mRNA expression of 
the pro-apoptotic Bax gene, which suggests that MPA is anti-apoptotic (Ory et al. 2001). 
Considering the above results, it is clear that no definitive conclusions can be drawn from the 
results of individual apoptosis-related genes, and that future studies should directly compare the 
effects of progestins on several both pro-apoptotic and anti-apoptotic genes.  
The effects of Prog on apoptosis-related genes have also previously been studied, with most studies 
indicating that Prog may be pro-apoptotic as it downregulates bcl-2 mRNA and protein expression 
(Formby & Wiley 1998; Moore et al. 2000), downregulates the mRNA expression levels of the 
apoptosis inhibitor, survivin (Formby & Wiley 1999), and upregulates p53 mRNA expression 
(Formby & Wiley 1998). However, effects may also be anti-apoptotic as at least one study has 
shown that Prog upregulates bcl-xL protein expression, while having no effect on Bax protein 
expression (Moore et al. 2000). Taken together, the above-mentioned evidence suggests that 
progestins promote breast cancer by inhibiting cell death (anti-apoptotic), while Prog can either 
promote (pro-apoptotic) or inhibit (anti-apoptotic) programmed cell death. 
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1.4.2.3. Migration and invasion 
Migration and invasion refers to the process of metastasis whereby cancerous cells from the primary 
tumour site spread to other organs in the body via the circulatory blood- and lymphatic systems 
(Chambers et al. 2002; Polyak 2007). To date, studies investigating the effects of progestins on 
migration and invasion are scarce. The research group of Simoncini has however investigated 
effects of MPA and DRSP, and showed that both these progestins increase migration and invasion 
of the T47D breast cancer cell line, with the increase by MPA being more pronounced (Fu et al. 
2008a). Interestingly, Prog also increased T47D breast cancer cell migration and invasion (Fu et al. 
2010; Diaz et al. 2012) to a greater extent than DRSP, but lesser extent than MPA (Fu, et al. 2008a; 
Fu, et al. 2008b). In a different study, Kariagina and co-workers showed that R5020 downregulates 
the protein expression of the epithelial adhesion protein E-cadherin, a protein, often downregulated 
in more invasive breast tumours (Kariagina et al. 2013). This result suggests that R5020 promotes 
invasion of T47D breast cancer cells (Kariagina et al. 2013). Interestingly, using T47D breast 
cancer cells that have been engineered to silence PR expression (T47D-Y), or express only PR-A 
(T47D-YA) or only PR-B (T47D-YB), Kariagina and co-workers (2013) showed that the R5020-
induced downregulation of E-cadherin is mediated via PR-B, suggesting that PR-B, but not PR-A, 
promotes R5020-induced breast cancer cell invasion (Kariagina et al. 2013). In contrast, a study by 
Bellance et al. (2013) using bi-inducible MDA-MB-231 breast cancer cells showed that PR-A and 
PR-B differentially contributed to the R5020-induced increase in breast cancer cell migration and 
invasion (Bellance et al. 2013).  
1.4.2.4. Angiogenesis 
Angiogenesis promotes tumour growth and metastasis by providing tumours with nourishment 
through the formation of new blood vessels (Hanahan & Weinberg 2000; Sledge & Miller 2003; 
Hsieh et al. 2005; Hanahan & Weinberg 2011). In terms of investigating the effects of progestins on 
angiogenesis, most studies have investigated the effects on the mRNA and protein expression levels 
of vascular endothelial growth factor (VEGF) (Hyder et al. 1998; Hyder et al. 2001; Wu et al. 2004; 
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Mirkin et al. 2005; Liang et al. 2007). VEGF is a very potent angiogenic growth factor (Hanahan & 
Weinberg 2000; Hanahan & Weinberg 2011) commonly overexpressed in metastatic breast cancer 
(Sledge & Miller 2003; Hsieh et al. 2005). However, these studies have been limited to the first 
generation progestins, MPA and NET, and the second generation progestin LNG. For example, 
MPA, NET and LNG have previously been shown to increase VEGF mRNA expression in T47D 
cells (Hyder et al. 1998; Mirkin et al. 2005), while MPA and NET increased VEGF protein 
expression in T47D cells (Hyder et al. 2001) and BT464 breast cancer xenografts (Liang et al. 
2010). In contrast to the above results, MPA and NET had no effect on VEGF protein expression in 
the MCF-7, MDA-MB-231 or ZR-75 breast cancer cell lines (Hyder et al. 1998). This could 
possibly be due to the fact that MCF-7, MDA-MB-231 and ZR-75 cells express little to no 
endogenous PR (Hyder et al. 1998).  
The effects of Prog on VEGF expression have been extensively studied, and like progestins, Prog 
has been shown to increase VEGF mRNA (Hyder et al. 1998; Wu et al. 2004; Mirkin et al. 2005) 
and protein (Hyder et al. 2001) expression in T47D cells and BT-474 breast cancer xenografts 
(Liang et al. 2010), while having no effect on VEGF protein expression in the MCF-7, MDA-MB-
231 and ZR-75 breast cancer cell lines (Hyder et al. 1998). Two separate studies by Hyder and co-
workers showed that the Prog-, MPA- and NET-induced upregulation of VEGF protein expression 
in T47D cells was mediated by the PR (Hyder et al. 1998; Hyder et al. 2001). In another study, Wu 
and co-workers (2004) attempted to delineate the role of the individual PR isoforms in the 
progestogen-induced upregulation of VEGF protein expression in T47D cells (Wu et al. 2004). 
Using T47D-Y, T47D-YA and T47D-YB cells, these authors showed that MPA, NET and Prog 
upregulates VEGF protein expression to a greater extent in the T47D-YB cells than in the T47D-
YA cells, while having no significant effect on the T47D-Y cells, suggesting that progestogen-
induced upregulation of VEGF is mainly mediated via PR-B (Wu et al. 2004). Furthermore, it has 
been shown that the VEGF gene is under the direct transcriptional regulation of the PR as the gene 
promoter contains three functional PRE sequences (Mueller et al. 2003). Taken together, these 
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results suggest that progestogens may be acting via PR-B to promote angiogenesis and ultimately 
breast cancer growth and metastasis.  
1.4.3. Steroid receptor crosstalk in breast cancer 
Multiple steroid receptors, in addition to the PR and ERα, have been implicated in the etiology and 
pathogenesis of breast cancer. For example, increased expression of ERβ and the AR in breast 
tumours correlate with good prognosis (Peters et al. 2009; Leygue & Murphy 2013). It is known 
that ERβ inhibits ERα-mediated breast cancer cell proliferation (Williams et al. 2008), while it has 
been shown that the AR  inhibits ERα-mediated transcriptional activation (Peters et al. 2009). In 
addition, glucocorticoids acting via the GR are known to have anti-proliferative and anti-apoptotic 
effects on breast cancer (Abduljabbar et al. 2015; reviewed in McNamara & Sasano 2015), and 
have also been shown to inhibit ERα-mediated breast cancer cell proliferation (Karmakar et al. 
2013). Moreover, Hopp et al. (2004) have shown that overexpression of PR-A in ER- and PR-
positive breast cancer negatively influences breast cancer treatment with the selective ER modulator 
tamoxifen, by causing tamoxifen resistance (Hopp et al. 2004). PR-A has in fact been shown to 
repress the activity of PR-B (Conzen 2008), as well as that of the ER, AR, MR and GR (Vegeto & 
Shahbaz 1993; Wen et al. 1994; McDonnell & Goldman 1994; McDonnell et al. 1994).  
Daniel and co-workers showed that in the absence of ligand, PR-B, ERα and the scaffolding protein 
proline-, glutamate- and leucine-rich protein 1 (PELP1) form transcriptional complexes at the 
promoter sequences of certain ER target genes, enhancing the responsiveness of MCF-7 breast 
cancer cells to E2, thus resulting in a more aggressive breast cancer phenotype (Daniel et al. 2015). 
In another study it was shown that in the presence of Prog, the PR inhibits breast tumour growth by 
associating with ERα and thereby altering the recruitment of ERα to the chromatin, which 
ultimately changes the transcriptional activity of ERα and activates a gene expression programme 
that favours a good prognosis (Mohammed et al. 2015). All of the above clearly indicates the 
complexity of crosstalk between steroid receptors in breast cancer. Interestingly, multiple steroid 
receptors have been implicated in the mechanism whereby MPA increases breast cancer. For 
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example, MPA has been shown to mediate its breast cancer promoting effects via the PR (Hyder et 
al. 1998; Hyder et al. 2001; Fu, et al. 2008a; Wargon et al. 2014) and the AR (Ochnik 2012). An 
example of steroid receptor crosstalk which is of particular importance for the present study is the 
reported crosstalk between the PR and ERα. Giulianelli et al. (2012) showed that ERα is required 
for MPA-induced gene regulation and breast cancer cell proliferation mediated by PR-B (Giulianelli 
et al. 2012).  
1.5. Conclusion 
The available clinical, epidemiological and experimental studies on progestins and breast cancer 
indicate an association between the use of progestins in HRT and increased risk of developing 
breast cancer, with the majority of research focussing on the first generation progestin MPA. A few 
studies have, however, examined the effects of the first generation progestin NET, and second 
generation progestin LNG, while only one or two have investigated newer generation progestins 
like GES and DRSP. Considering that a number of different progestins are available for clinical use, 
and that small changes in their structure can lead to different biological effects, it is possible that not 
all progestins would increase the risk of breast cancer. Furthermore, due to concerns that the use of 
progestins in HRT is associated with an increased risk of breast cancer, the compounded bio-
identical hormone, bProg, is sometimes used as an alternate, “safer” hormone therapy. Considering 
that progestins and bProg are PR ligands, and that the PR plays an important role in breast cancer 
development and progression, it is crucial to understand how the actions of the compounds via the 
PR, specifically the most active isoform PR-B, may be differentially affecting breast cancer risk. 
Studies directly comparing the activity of progestins from different generations via PR-B in the 
same model system are lacking. Interestingly, emerging evidence shows that the activity of MPA 
via PR-B requires the presence of ERα (Giulianelli et al. 2012). As the ER exists as two subtypes, 
ERα and ERβ, a question that arises is whether ERβ is also required for PR-B mediated effects of 
MPA, and/or other progestins. Understanding the mechanisms whereby progestins may or may not 
contribute to the development of breast cancer could better inform decisions in terms of the choice 
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of progestin for therapeutic use or the development of new therapies for the treatment of breast 
cancer.  
1.6. Hypothesis and aims 
It is evident that increased risk of breast cancer is associated with the clinical use of some 
progestins. Whether this risk is applicable to all progestins is not clear. Surprisingly, the role of 
the PR in mediating the effects of progestins, and the subsequent effects on breast cancer is not 
well studied. The primary hypothesis of this study was that selected progestins from the 
different generations would display differential transcriptional activities and proliferative effects 
via PR-B, while no difference would be observed between Prog and bProg. Furthermore, 
knowing that Giulianelli et al. (2012) has shown that ERα is required for MPA-induced breast 
cancer cell proliferation, and that ERα is known to be pro-proliferative, while ERβ is anti-
proliferative, it was hypothesised that ERα, but not ERβ, would be required for progestin-
induced gene regulation and breast cancer cell proliferation via PR-B. 
 
The aims of this study were as follows: 
To compare PR-B mediated activation and repression of transcription by Prog, bProg and 
selected progestins from different generations on (i) synthetic PRE- and NFκB-containing 
promoters in the COS-1 cell line and (ii) endogenous PRE- and NFκB-containing genes in the 
T47D breast cancer cell line. Furthermore, the relative agonist efficacies and potencies of the 
progestogens on synthetic PRE- and NFκB-containing promoters via PR-B were also compared 
with each other. 
 
To determine whether ERα and/or ERβ is required for PR-B mediated activation and repression 
by Prog, bProg and selected progestins, in the COS-1 cell line and T47D breast cancer cell line, 
respectively. 
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To compare the agonist efficacies and potencies of Prog, bProg and selected progestins from 
different generations for proliferation of the T47D breast cancer cell line.  
 
To determine whether ERα and/or ERβ is required for Prog, bProg and/or progestin-induced 
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2.1. Test compounds 
The progestogens used in this study are listed in Table 2.1. R5020 was obtained from PerkinElmer 
Life and Analytical Science, South Africa, while bProg was a kind gift from the Compounding 
Pharmacy of South Africa, Johannesburg. All other progestogens were purchased from Sigma-
Aldrich, South Africa. The ERα selective antagonist methyl-piperidino-pyrazole dihydrochloride 
hydrate (MMP) and the ERβ selective antagonist 2-phenyl-3-(4-hydroxyphenyl)-5,7-
bis(trifluoromethyl)-pyrazolo[1,5-alpha]pyrimidine (PHTPP) were purchased from Whitehead 
Scientific, South Africa and Sigma-Aldrich, South Africa, respectively. The inflammatory cytokine, 
tumor necrosis factor-alpha (TNFα) was obtained from PeproTech, USA and used at a final 
concentration of 0.02 µg/ml for realtime quantitative PCR (qPCR) and 0.002 µg/ml for promoter-
reporter assays. The lower concentration of TNFα for promoter-reporter assays has previously been 
optimised in the Africander laboratory (Meghan Perkins, PhD student). All test compound stock 
solutions were prepared in 100% ethanol (EtOH) and stored at -20°C. These compounds were 
diluted 1000X in serum-free culturing medium, so that the final concentration of EtOH was 0.1% 
(v/v). Thus, 0.1% (v/v) EtOH served as a vehicle control in all experiments.  
Table 2.1 Test compounds used in this study. 
Compound Classification 
Progesterone (Prog) Natural progestogen 
Bio-identical progesterone (bProg) Semi-synthetic 
Progestins Synthetic 
Promegestone (R5020) 
PR-selective agonist widely used as an 
experimental tool 
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2.2. Cell culture 
The PR- and ER-positive T47D human breast cancer epithelial cell line was a kind gift from 
Prof.  Iqbal Parker (University of Cape Town, South Africa) and was maintained in Roswell Park 
Memorial Institute (RPMI) 1640 medium (Sigma-Aldrich, South Africa) supplemented with 10% 
(v/v) fetal calf serum (FCS) (The Scientific Group, South Africa), 10 mM HEPES (Sigma-Aldrich, 
South Africa), 100 IU/ml penicillin and 100 µg/ml streptomycin (Gibco-BRL Life Technologies, 
United Kingdom). The COS-1 monkey kidney cell line was obtained from the American Type 
Culture Collection (ATCC, USA) and maintained in phenol-red Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Sigma-Aldrich, South Africa) supplemented with 10% (v/v) FCS, 100 IU/ml 
penicillin and 100 µg/ml streptomycin. All cell lines were maintained in 75 cm
2
 culture flasks 
(Greiner Bio-One International, Austria) at 37°C, in an atmosphere of 90% humidity and 5% CO2. 
Cell lines were regularly tested for mycoplasma infections using Hoechst stain (Freshney 1987), 
and only mycoplasma negative cells were used in experiments.  
2.3. Plasmids 
The pMT-hPR-B plasmid expressing human PR-B (previously described by Cairns et al. 1993), was 
a kind gift from Prof. Sam Okret (Karolinska Institute, Sweden), whereas the plasmids expressing 
the human ERα (pSG5-ERα) and ERβ (pSG5-ERβ) (Flouriot et al. 2000) were obtained from Prof. 
Frank Gannon (European Molecular Biology Laboratory, Germany). The pTAT-2xPRE-E1b-
luciferase promoter-reporter plasmid, which is driven by the E1b promoter and contains two copies 
of the rat tyrosine aminotransferase (TAT)-PRE (previously described by Sui et al. 1999), was a 
kind gift from Prof. G. Jenster (Erasmus University of Rotterdam, Netherlands), while the 5xNFκB-
luciferase promoter-reporter plasmid containing five copies of the NFκB binding site upstream of 
the luciferase reporter gene was purchased from Strategene (Houston, Texas, USA). The pGL2-
basic vector, purchased from Promega (Madison, USA), was used as a filler plasmid to ensure that 
the total amount of transfected DNA remained constant in all experiments. 
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2.4. Plasmid DNA preparation  
Calcium chloride competent DH5α Escherichia coli (E. coli) cells were transformed with the 
respective expression vectors mentioned in Section 2.3 using the heat shock method (Cohen et al. 
1972). The transformed E. coli cells were grown overnight on Luria Bertani (LB) agar (Sigma-
Aldrich, South Africa) (Addendum A) plates containing ampicillin (Sigma-Aldrich, South Africa) 
at a final concentration of 50 µg/ml. All the plasmids used in this study contained an ampicillin 
resistance gene. A single colony was selected, inoculated into 25 ml LB medium (Sigma-Aldrich, 
South Africa) containing ampicillin (50 µg/ml) and grown at 37°C for 6 hours. Two hundred and 
fifty microliters of the starter culture was transferred to 250 ml LB medium containing ampicillin 
(50 µg/ml), and grown for 12-16 hours at 37°C. The cultures were then centrifuged at 6 000 x g for 
10 minutes at 4°C in order to collect the bacterial cells. Once the supernatant was discarded, the 
plasmid DNA was isolated and purified from the E. coli cells using the Macherey-Nagel 
Nucleobond® Xtra Maxi kit according to the manufacturer’s instructions. Briefly, the pellets were 
resuspended in 12 ml resuspension buffer containing RNase A. The cells were then lysed by adding 
12 ml lysis buffer, inverting the tube 5 times and incubating the suspension for 5 minutes at room 
temperature. Following incubation, the lysing process was stopped by adding 12 ml neutralization 
buffer and inverting the solution 15 times. The plasmid DNA was purified by using the 
Nucleobond® Xtra Maxi column with an inserted filter. Prior to applying the lysate, the filter as 
well as the column was first equilibrated by applying 25 ml equilibration buffer. The lysate was 
applied to the filter in order to remove all cell debris before the eluate was passed through the 
column. Thereafter, 15 ml equilibration buffer was applied to the filter and the eluate was once 
again passed through the Nucleobond® column. The filter was discarded and the column washed 
with 25 ml wash buffer, prior to the addition of 15 ml elution buffer. The eluate containing the 
plasmid DNA was collected in a 50 ml centrifuge tube and 10.5 ml isopropanol (room temperature) 
was added. To precipitate the DNA, the solution was vortexed and subsequently centrifuged at 
15 000 x g for 30 minutes at 4°C. The supernatant was discarded and the DNA pellet was washed 
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with 5 ml 70% (v/v) EtOH, followed by centrifugation at 15 000 x g for 5 minutes at room 
temperature. The DNA pellet was allowed to dry at room temperature before resuspension in 1 ml 
nuclease-free water. The DNA concentration was determined on a NanoDrop 1000 (Thermo Fisher 
Scientific, South Africa) using the 260 nm/280 nm ratio, and the size and integrity of the plasmid 
DNA was analysed by restriction enzyme digests and agarose gel electrophoresis.  
2.5. Promoter-reporter assays 
For both transactivation and transrepression assays, the COS-1 cell line was maintained as 
described in Section 2.2 and seeded into 10 cm dishes (Whitehead Scientific, South Africa) at a cell 
density of 2 x 10
6 
cells. Twenty-four hours later the cells were washed with pre-warmed sterile 
phosphate buffered saline (PBS) (Sigma-Aldrich, South Africa) and 10 ml phenol red-free DMEM 
supplemented with 10% (v/v) charcoal-stripped FCS (CS-FCS), 100 IU/ml penicillin and 100 µg/ml 
streptomycin (hereafter referred to as supplemented phenol red-free DMEM) was added.  
For transactivation assays: Using the X-tremeGENE HP DNA transfection reagent as per the 
manufacturer’s instructions, the COS-1 cells were transiently transfected with 0.9 µg of the pMT-
hPR-B expression vector and 9 µg of the pTAT-2xPRE-E1b-luciferase promoter-reporter construct, 
in the presence of either 0.9 µg pSG5-hERα, pSG5-hERβ or pGL2-basic (filler plasmid). The latter 
ensured a constant amount of total DNA (10.8 µg/10 cm dish) in all experimental conditions. 
Following a 24 hour period, the cells were replated into 96-well cell culture plates (Whitehead 
Scientific, South Africa) at a cell density of 1 x 10
4 
cells per well in supplemented phenol red-free 
DMEM. The next day, the cells were washed with pre-warmed PBS and treated for 24 hours with 
either 0.1% (v/v) EtOH (vehicle control) or increasing concentrations of R5020, Prog, bProg, MPA, 
NET-A, LNG, GES and DRSP (hereafter referred to as the test compounds) in unsupplemented 
phenol red-free DMEM. The cells were then washed with PBS, lysed by adding 25 µl passive lysis 
buffer (Addendum A) and stored at -20°C. The cell lysates were thawed and 5 µl lysate was used to 
determine the luciferase activity using the Promega Luciferase Assay System (Promega, Madison, 
USA) and a Veritas™ microplate luminometer (Whitehead Scientific, South Africa). To normalise 
Stellenbosch University  https://scholar.sun.ac.za
37 
the luciferase activity, the protein concentration (mg/ml) of each lysate was determined using the 
Bradford protein determination method (Bradford, 1976). Normalising results in this manner for 
bulk transfections, followed by replating into a number of wells, is a widely accepted method 
(Visser et al. 2013). Expression of the steroid receptors were further validated by western blotting. 
When comparing transactivation activity of the test compounds via PR-B, results are expressed as 
relative luciferase activity with 1 µM R5020 set as 100%, and all other test compounds set relative 
to this. Results for PR-B in the absence and presence of ERα or ERβ are expressed as fold induction 
with 0.1% (v/v) EtOH for PR-B alone set as 1, and all other responses set relative to this.  
For transrepression assays: The COS-1 cells were transiently transfected with 1.5 µg of the pMT-
hPR-B expression vector and 3 µg of the 5xNFκB-luciferase promoter-reporter construct, in the 
presence of either 1.5 µg pSG5-hERα, pSG5-hERβ or pGL2-basic, using the X-tremeGENE HP 
DNA transfection reagent according to the manufacturer’s instructions. The pGL2-basic filler 
plasmid was transfected to ensure a constant amount of total DNA (6 µg/10 cm dish) in all 
experimental conditions. The next day, the cells were replated into 96-well cell culture plates at a 
cell density of 1 x 10
4 
cells per well in supplemented phenol red-free DMEM. Following a 24 hour 
period, the cells were washed with pre-warmed PBS and incubated for 24 hours with 
unsupplemented phenol red-free DMEM containing (i) 0.1% (v/v) EtOH in the absence or presence 
of 0.002 µg/ml TNFα or (ii) 0.002 µg/ml TNFα in the presence of increasing concentrations of the 
test compounds. Cells were washed with PBS, lysed and the cell lysates analysed as described for 
transactivation. The luciferase values obtained for all samples were normalised to the protein 
concentration (mg/ml) for each sample. TNFα-induction was plotted relative to 0.1% (v/v) EtOH 
alone set as 1. TNFα-induction was set as 100%, and the repression by each test compound was set 
relative to this.  
2.6. Western blot analysis 
COS-1 cells were maintained and transfected as described in Sections 2.2 and 2.5, respectively, and 
seeded into 12-well cell culture plates at a cell density of 1 x 10
5
 cells per well. Positive controls 
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were prepared by transiently transfecting cells with 250 ng of the expression vector for the 
appropriate steroid receptor, while untransfected COS-1 cells were used as a negative control. Cells 
were grown until confluency was reached, washed with PBS and subsequently lysed in 80 µl 2x 
Laemmli buffer (Addendum A). In order to denature the proteins, cell lysates were boiled at 97°C 
for 10 minutes before separation on a 10% SDS-polyacrylamide gel at 200 V for 45 minutes using 
1x SDS-PAGE running buffer (Addendum A).  The PageRuler™ Prestained Protein Ladder 
(Thermo Fisher Scientific, South Africa) was used to determine protein sizes. After electrophoresis, 
the proteins were transferred to Hybond-ECL nitrocellulose membranes (Amersham Biosciences, 
South Africa) by electroblotting at 180 mA for 90 minutes using ice-cold 1x transfer buffer 
(Addendum A). Membranes were subsequently blocked for 90 minutes using 10% (w/v) fat-free 
milk powder prepared in 1x TRIS buffered saline (TBS) containing 0.1% (v/v) Tween 20 (Sigma-
Aldrich, South Africa) (TBST) (Addendum A). Following incubation, membranes were rinsed 
using 1x TBST and subsequently probed with primary antibodies specific to PR-A/B (NCL-L-PGR-
312, Leica Biosystems, United Kingdom), ERβ (ab92306, Abcam), ERα (sc-543, Santa Cruz 
Biotechnology Inc., Europe), GR (sc-8992), MR (sc-11412), AR (sc-7305) and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (sc-47724) for 16 hours at 4°C. GAPDH expression was used 
as a loading control. The antibody dilutions used during this study are indicated in Table 2.2. 
Following one 15 minute and three 5 minute washes using 1x TBST, membranes were incubated 
with either the goat anti-rabbit (sc-2030) or goat anti-mouse (sc-2005) horseradish peroxidase 
(HRP)-conjugated secondary antibody (Santa Cruz Biotechnology Inc., Europe) (see Table 2.2) for 
90 minutes at room temperature. The membranes were washed as above and the proteins visualized 
using Clarity™ Western ECL substrate (Bio-Rad, South Africa) and the Thermo Fisher Scientific 
MyECL™ Imager (Separations, South Africa). 
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Table 2.2 Dilutions of primary and secondary antibodies used for western blotting. 
 
2.7. RNA isolation 
The human T47D breast cancer cell line was maintained as described in Section 2.2 and seeded into 
12-well cell culture plates (Whitehead Scientific, South Africa) at a cell density of 1 x 10
5
 cells per 
well. After the cells had settled, cells were washed with pre-warmed sterile PBS before the addition 
of supplemented phenol red-free DMEM and incubation for 24 hours. Cells were treated with 
unsupplemented phenol red-free DMEM containing either (i) 0.1% (v/v) EtOH or 1 nM of the test 
compounds (transactivation) or (ii) 0.1% (v/v) EtOH alone in the absence or presence of 0.02 µg/ml 
TNFα or (iii) 0.02 µg/ml TNFα in the presence of 1 nM of the test compounds (transrepression), in 
the absence and presence of 10 µM receptor-selective antagonists. Following incubation for 24 
hours (transactivation) or 6 hours (transrepression), the cells were lysed by adding 400 µl 
TriReagent® (Sigma-Aldrich, South Africa) to each well. The lysates were transferred to 1.5 ml 
microcentrifuge tubes and 80 µl chloroform was added. The samples were vortexed for 15 seconds, 
Primary Antibody Dilution Secondary Antibody Dilution 
PR-A/B 1:1 000 Goat-anti-mouse 1:2 000 
ERα 1:1 000 Goat-anti-rabbit 1:1 000 
ERβ 1:500 Goat-anti-rabbit 1:1 000 
AR 1:1 000 Goat-anti-mouse 1:5 000 
MR 1:1 000 Goat-anti-rabbit 1:4 000 
GR 1:6 000 Goat-anti-rabbit 1:4 000 
GAPDH 1:4 000 Goat-anti-mouse 1:6 000 
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incubated for 2-3 minutes at room temperature, and then centrifuged at 12 000 x g for 15 minutes at 
4°C. The centrifugation step separated the samples into three distinct phases namely, a clear 
aqueous phase at the top containing RNA, a middle phase containing DNA and a bottom pink phase 
containing protein. The top phase containing the RNA was transferred to clean 1.5 ml 
microcentrifuge tubes and an equal volume of ice-cold isopropanol was added. Samples were 
subsequently vortexed, incubated for 15 minutes at room temperature and centrifuged at 12 000 x g 
for 10 minutes at 4°C. The supernatant was discarded and the RNA pellets were washed with 500 µl 
75% (v/v) EtOH in diethyl pyrocarbonate (DEPC) treated water. The samples were vortexed for 1 
minute and subsequently centrifuged at 7 500 x g for 15 minutes at 4°C. The supernatant was 
discarded and the RNA pellets were allowed to air dry on ice for 5-10 minutes. Each RNA pellet 
was subsequently dissolved in 15 µl DEPC treated water. The purity of the RNA was determined by 
calculating the concentrations from the absorbances at 260 and 280 nm using a NanoDrop1000 
(Thermo Scientific, Wilmington, USA) and the RNA concentrations were subsequently calculated, 
while the integrity of the RNA was assessed by the presence of intact 28S and 18S ribosomal RNA 
bands on a 1% (w/v) denaturing formaldehyde agarose gel. A representative gel is shown in 
Addendum B (Figure B1). All RNA samples were subsequently stored at -80°C. 
2.8. cDNA synthesis  
cDNA was synthesised by reverse transcribing the total RNA extracted from the T47D breast 
cancer cells using the Promega ImProm-II reverse transcription system as per the manufacturer’s 
instructions (Anatech, South Africa). Briefly, 0.5 µg total RNA and 0.25 µl oligo(dT)15 primer (at a 
final concentration of 25 ng/µl) were added into a thin-walled PCR tube. This was followed by the 
addition of nuclease-free water to a final volume of 2.5 µl. The mixture was incubated at 70°C for 5 
minutes to denature the RNA and was subsequently placed on ice. Following incubation on ice for 5 
minutes, the rest of the components needed for the reverse transcription reaction were added in the 
following order: nuclease-free water to a final volume of 7.5 µl per sample, 2 µl Im-Prom-II 5 x 
reaction buffer, 0.6 µl MgCl2 (at a final concentration of 1.5 mM), 0.5 µl deoxynucleotide (dNTP) 
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mix with a final concentration of 0.5 nM for each nucleotide, 0.25 µl recombinant RNasin 
ribonuclease inhibitor (10 U per reaction), and 0.5 µl ImProm-II reverse transcriptase (80 U per 
reaction). For the reverse transcription reaction to take place the samples were incubated for 5 
minutes at 25°C to allow annealing of the primers, followed by incubation for 1 hour at 42°C for 
extension. Finally, samples were incubated for a further 15 minutes at 70°C in order to inactivate 
the Im-Prom-II reverse transcriptase enzyme. All cDNA samples were stored at -20°C. 
2.9. Realtime quantitative PCR (qPCR) 
Realtime qPCR was performed using the Roche LightCycler® 96 in order to determine the relative 
mRNA expression levels of c-myc, interleukin (IL)-8 and GAPDH. The latter gene was used as an 
internal control (reference gene) since the Africander laboratory has previously shown that its 
expression is not regulated by the test compounds (personal communication). The details of the 
primers used for amplification are summarized in Table 2.3. Reagents from the LightCycler® 480 
SYBR Green I Master kit (Roche Applied Science, South Africa) were used, and the reaction 
mixture in each well of the PCR plate was as follows: forward and reverse primers (final 
concentration of 0.5 µM each), 5 µl SYBR Green I, PCR-grade water to a final volume of 9 µl, and 
1 µl of either cDNA or PCR-grade water (negative control). Once all the samples were prepared, 
the Roche FastStart Taq polymerase was activated by incubating the samples at 95°C for 10 
minutes. The subsequent PCR amplification consisted of three steps: a denaturation step at 95°C for 
10 seconds, a 10 second annealing step at the appropriate temperature indicated in Table 2.3, and an 
elongation step of 10 seconds at 72°C. The PCR cycle was repeated 45 times. Melting curve 
analysis (Addendum B: Figure B3) and agarose gel electrophoresis (Addendum B: Figure B4) were 
performed to confirm the presence of a single amplicon and the amplicon size, respectively. The 
primer efficiencies (Table 2.3) and relative transcript levels were determined as previously 
described by Pfaffl et al. (2001). Further details on the qPCR method can be found in Addendum B. 
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2.10. Cell proliferation assays  
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay is a colorimetric 
assay based on the principle that mitochondrial succinate dehydrogenase reduces soluble yellow 
MTT to form insoluble purple formazan crystals. These crystals are then dissolved, followed by 
spectrophotometric analysis. The absorbance values are a measure of the number of viable cells 
present since the soluble MTT can only be reduced to an insoluble formazan precipitate by 
metabolically active cells (Mosmann 1983). The human T47D breast cancer cell line was 
maintained as described in Section 2.2 and seeded into 96-well cell culture plates at a cell density of 
1 x 10
4 
cells per well. On day two, the cells were washed with sterile pre-warmed PBS before the 
addition of supplemented phenol red-free DMEM. The following day the cells were treated with 
either 0.1% (v/v) EtOH, or increasing concentrations of the test compounds. Alternatively, cells 
were treated with 1 nM test compound in the absence and presence of 10 µM receptor-selective 
antagonists and incubated for 72 hours. Four hours before the incubation period lapsed, the assay 
medium was replaced with 150 µl unsupplemented phenol red-free DMEM and 50 µl 5 mg/ml 
MTT solution (Addendum A) (Sigma-Aldrich, South Africa). Plates were returned to the incubator 
for the remaining 4 hours, followed by the aspiration of the medium and the addition of 200 µl 
dimethyl sulfoxide (DMSO) (Merck, South Africa) (solubilising agent) to each well. The formazan 
crystals were dissolved by pipetting up and down and the plates were subsequently covered in foil 
and placed on an orbital shaker at room temperature for 5 minutes. The absorbances were 
subsequently measured at 550 nm using a BioTek® Power Wave 340 microplate spectrophotometer 
(Analytical and Diagnostic Products, South Africa). Proliferation is shown as fold induction relative 
to 0.1% (v/v) EtOH (vehicle control) set as 1. 
2.11. Data manipulation  
Data manipulations, graphical presentations and statistical analysis were performed using GraphPad 
Prism® version 5 (GraphPad Software, Inc., San Diego, CA). Non-linear regression and the 
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unpaired t-test (two-tailed) were used for statistical analysis of all data with the exception of MTT 
assays. For MTT assays, either non-linear regression one-way ANOVA column analysis with the 
Newman-Keuls (compares all pairs of columns) post-test, or two-way ANOVA analysis of variance 
with Bonferroni (compares all pairs of columns) post-test, was used. Statistical significance are 
indicated by *, ** or ***, to indicate p<0.05, p<0.01 or p<0.001, respectively, while non-
statistically significant results (p>0.05) are indicated by ns. Furthermore, the letters a, b, c, d are 
also used to indicate statistically significant differences, with values that differ significantly from 
each other being assigned different letters. The error bars represent the standard error of the mean 
(SEM) of two to three independent experiments, except for realtime qPCR for which only a single 
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3.1. Most progestins display similar relative agonist efficacies and potencies to 
each other for transactivation via PR-B on a synthetic PRE-containing promoter 
The relative agonist efficacies (maximal response a ligand can elicit) and potencies (EC50; 
concentration of ligand that induces half the maximal response) of all the progestogens for 
transactivation via PR-B on a synthetic PRE were compared to each other. The COS-1 monkey 
kidney cell line was transiently transfected with the pMT-hPR-B expression vector, a PRE driven 
promoter-reporter construct containing two copies of a PRE site linked to the luciferase reporter 
gene, and the pGL2-basic empty vector to a total amount of 10.8 μg DNA (previously optimised in 
the Africander laboratory). The cells were subsequently treated with either 0.1% (v/v) EtOH 
(vehicle control) or increasing concentrations of R5020, Prog, bProg, MPA, NET-A LNG, GES or 
DRSP (hereafter referred to as either progestogens or test compounds) for 24 hours. R5020 is a 
well-known PR-selective agonist often used as a positive control when investigating effects via the 
PR (Giannoukos et al., 2001; Shatnawi et al., 2007). The results are graphically presented in figure 
3.1A and 3.1B, while the values for the relative agonist efficacies and potencies of the test 
compounds for transactivation via PR-B are summarised in Table 3.1. The natural progestogen Prog 
as well as the semi-synthetic, bio-identical progestogen bProg, exhibited similar efficacies to each 
other, but significantly lower efficacies than R5020 (figure 3.1A; Table 3.1). Interestingly, Prog 
displayed a similar agonist potency to that of R5020, while bProg was significantly more potent 
than both R5020 (p<0.01) and Prog (p<0.001). NET-A, LNG, GES and DRSP all displayed similar 
efficacies to each other and R5020 (figure 3.1B; Table 3.1). Surprisingly, however, MPA displayed 
a much lower maximal response than R5020. In terms of potency, GES displayed a similar potency 
to R5020, and although MPA, NET-A, LNG and DRSP appeared to be less potent than R5020, 
these differences were not statistically significant. When comparing the progestins to natural Prog, 
the results in Table 3.1 show that MPA displayed a similar efficacy to Prog, while NET-A was 
more efficacious than Prog. Although not statistically significant, LNG, GES and DRSP appeared 
to display greater maximal responses than Prog. Interestingly, MPA, NET-A and LNG displayed 
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similar potencies to that of Prog, while DRSP was less potent and GES was more potent than Prog. 
The efficacies and potencies of the progestins were also compared to that of bProg, and results 
show that MPA displayed a similar efficacy to that of bProg, while NET-A displayed a greater 
maximal response than bProg (figure 3.1A and 3.1B; Table 3.1). Although not statistically 
significant, LNG, GES and DRSP appeared to be more efficacious than bProg. Surprisingly, all the 
progestins investigated in this study were less potent than bProg.  
3.2. Neither ERα nor ERβ is required for progestogen-induced transactivation 
via PR-B on a synthetic PRE-containing promoter 
In a recent study, Giulianelli et al. (2012) reported that ERα is required for the PR-B mediated 
effects of MPA. This raised the question of whether ERα is also needed for the transcriptional 
activation of PR-B by other progestogens. We thus transiently transfected COS-1 cells with the 
pMT-hPR-B expression vector and the pTAT-2xPRE-E1b-luciferase promoter-reporter construct, in 
the absence (pGL2-basic empty vector) and presence of the pSG5-hERα expression vector, 
followed by the treatment of the cells with 0.1% (v/v) EtOH or increasing concentrations of MPA 
for 24 hours. The results in figure 3.2 show that ERα had no effect on the relative maximal response 
or agonist potency of MPA via PR-B, suggesting that ERα is not required for MPA-induced PR-B-
mediated gene expression in our system. Considering that two distinct ER subtypes with vastly 
different functions exist (Deroo & Korach 2006; Hartman et al. 2009), we also determined the 
effects of ERβ on the PR-B-mediated relative agonist efficacies and potencies of MPA for 
transactivation. COS-1 cells were thus transfected as before, except that the pSG5-hERβ rather than 
the pSG5-hERα expression vector was transfected. Following treatment with 0.1% (v/v) EtOH or 
increasing concentrations of MPA for 24 hours, the results showed that the presence of ERβ 
significantly decreased the maximal response of MPA via PR-B (p<0.05), however, statistical 
significance could not be obtained when comparing the maximal responses for MPA via PR-B in 
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the presence of ERα versus ERβ. Although it appears that the relative agonist potency of MPA 
decrease in the presence of ERβ, this difference was not statistically significant (figure 3.2). 











































































































Figure 3.1. (A) Prog and bProg display similar agonist efficacies, but not potencies for transactivation 
via PR-B. The COS-1 cell line was transiently transfected with 900 ng of the pMT-hPR-B expression vector, 
9 000 ng of the pTAT-PRE-E1b-luciferase promoter-reporter construct and 900 ng of the pGL2-basic empty 
vector. Cells were incubated with 0.1% EtOH or increasing concentrations of R5020 (♦), Prog (●) or  
bProg (□) for 24 hours. (B) LNG, GES and DRSP appear to display greater maximal responses than 
Prog via PR-B, while MPA appears to be less efficacious than Prog. COS-1 cells were transiently 
transfected as above and incubated with 0.1% EtOH or increasing concentrations of R5020 (♦), Prog (●), 
MPA (▲), NET-A (■), LNG (▼), GES (◊) or DRSP (*) for 24 hours. For both (A) and (B) induction is 
shown as relative luciferase activity expressed as percentage, with 10
-6 
M R5020 set as 100% and all other 
test compounds set relative to this. Result shown is the average of at least two independent experiments, with 
each condition performed in triplicate ( SEM).  
A 
B 
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Table 3.1. Relative agonist efficacies (maximal response (MAX) in %) and potencies (expressed as 
EC50 in M) of the test compounds for transactivation via PR-B.
a 
Test compounds Classification MAX (%) ± SEM EC50 (M) ± SEM 
R5020 PR-selective agonist 100.0 ± 0.0 6.97 × 10
-11
 ± 2.90 
Prog Natural progestogen 43.80 ± 10.13 1.36 × 10
-10




37.09 ± 8.44 2.65 × 10
-12






25.37 ± 9.86 4.51 × 10
-10  
± 2.18   
NET-A 93.57 ± 3.92 2.96 × 10
-10






86.29 ± 27.94 2.45 × 10
-10  






98.07 ± 28.76 3.61 × 10
-11 






68.61 ± 26.83 1.36 × 10
-9
 ± 0.77 
  a
Data shown in figure 3.1A and 3.1B were analysed to obtain the relative maximal response (MAX) ± SEM 
and EC50 ± SEM values for each test compound. MAX values are expressed as a percentage relative to 10
-6
 
M R5020 = 100% and statistical analysis of these values indicated that R5020 vs. Prog and bProg (p<0.05); 
Prog vs. bProg (p>0.05); R5020 vs. MPA (p<0.01); R5020 vs. NET-A, LNG, GES and DRSP (p>0.05); Prog 
vs. NET-A (p<0.05); Prog vs. MPA, LNG, GES and DRSP (p>0.05); MPA vs. NET-A (p<0.05); NET-A vs. 
LNG, GES and DRSP (p>0.05); MPA vs. LNG vs. GES vs. DRSP (p>0.05); bProg vs. NET-A (p<0.05); 
bProg vs. MPA, LNG, GES and DRSP (p>0.05). Statistical analysis of EC50 values indicated that R5020 vs. 
Prog (p>0.05); R5020 vs. bProg (p<0.01); Prog vs. bProg (P<0.001); R5020 vs. MPA, NET-A, LNG, GES 
and DRSP (p>0.05); Prog vs. GES and DRSP (p<0.05); Prog vs. MPA, NET-A and LNG (p>0.05); GES vs. 
MPA, NET-A and DRSP (p<0.05); MPA vs. NET-A vs. LNG vs. DRSP (p>0.05); LNG vs. GES (p>0.05); 
bProg vs. MPA, NET-A and DRSP (p<0.001); bProg vs. LNG (p<0.01); bProg vs. GES (p<0.05).  
 
Having shown that ERβ, but not ERα, can modulate the PR-B-mediated effects of MPA for 
transactivation, and considering that it is known that MPA does not to bind to the ER (Teulings et 
al. 1980), we postulated that the decrease in the PR-B-mediated effects of MPA in the presence of 
ERβ, and not in the presence of ERα, may be due to ERβ, but not ERα, downregulating PR-B 
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protein expression levels. Using western blot analysis we thus determined the effects of the ER 
subtypes on the protein levels of PR-B overexpressed in COS-1. Surprisingly, results in figure 3.3A 
and 3.3B showed that, in the absence of ligand, both ERα and ERβ significantly downregulated PR-
B protein expression levels (~65.8% (p<0.001) and ~58.5% (p<0.01), respectively). Notably, co-
expression of PR-B and either ERα or ERβ did not affect the protein expression of either ERα 
(figure 3.3C) or ERβ (figure 3.3D). Next, we determined whether the decrease in PR-B protein 
expression levels observed in the absence of the progestogens and presence of the ER subtypes 
correlated with the effects of the ER subtypes on basal PR-B-mediated transcriptional activity. 
Interestingly, results in figure 3.3F showed that in the absence of ligand, ERβ decreased (p<0.001) 
the basal level of transcription of PR-B on a simple synthetic PRE-containing promoter (figure 
3.3E) which may be explained by the observed decrease in PR-B protein levels (figure 3.3B). 
Surprisingly, however, despite the decrease in PR-B protein levels observed in the presence of ERα 
(figure 3.3B), ERα increased (p<0.001) the basal level of transcription of PR-B (figure 3.3F).  














































PR-B PR + ERα PR + ERβ 
MAX (%) ± SEM 100 ± 0.0 89.84 ± 35.03 53.10 ± 16.60 
EC50 (M) ± SEM 4.51 × 10
-10  
± 2.18 2.97 × 10
-10  




Figure 3.2 legend on next page. 
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Figure 3.2. ERα has no effect on the PR-B-mediated agonist maximal response or potency of MPA, 
while ERβ significantly decreases the maximal response of MPA and appears to decrease the potency. 
COS-1 cells were transiently transfected with 900 ng of the pMT-hPR-B expression vector and 9 000 ng of 
the pTAT-PRE-E1b-luciferase promoter-reporter construct, in the absence (900 ng pGL2-basic) and 
presence of 900 ng of either the pSG5-hERα or pSG5-hERβ expression vector. The cells were subsequently 
incubated with increasing concentrations of MPA for 24 hours. Induction is shown as relative luciferase 
activity with PR-B in the presence of 0.1% EtOH set as 1, and all other responses set relative to this. Result 
shown is the average of at least two independent experiments, with each condition performed in triplicate ( 
SEM). Data were analysed to obtain the relative maximal response (MAX) ± SEM and EC50 ± SEM values 
for MPA via PR-B or PR-B in the presence of ERα (PR-B + ERα) or ERβ (PR-B + ERβ), respectively. MAX 
of MPA via PR-B alone was set as 100%, and the MAX of MPA via PR-B in the presence of ERα or ERβ 
calculated relative to this. Statistical analysis of the MAX values indicated the following: PR-B vs. PR-B + 
ERα (p>0.05); and PR-B vs. PR-B + ERβ (p<0.05). Statistical analysis of the EC50 values indicated that PR-
B vs. PR-B + ERα and PR-B vs. PR-B + ERβ (p>0.05).  
 
Knowing that the ER and PR are co-expressed in ~70% of all breast cancers (Lange 2008), and that 
women not only use MPA, but also other progestins for HRT and contraception, we next 
determined whether ERα and/or ERβ could modulate the relative agonist efficacies and potencies of 
the selected progestins investigated in this study. COS-1 cells transfected with PR-B in the absence 
and presence of ERα or ERβ, were treated with increasing concentrations of R5020, Prog, bProg, 
NET-A, LNG, GES and DRSP for 24 hours (figure 3.4A-G). In contrast to the effects observed for 
MPA, the presence of ERα significantly decreased the efficacies of all the other progestogens 
tested. Interestingly, the presence of ERα caused a decrease in the relative agonist potency of Prog, 
whilst having no statistically significant effects on the potencies of any of the other progestogens. 
The results in figure 3.4A-G showed that ERβ, like ERα, decreased the maximal responses of 
R5020, Prog, bProg, NET-A, LNG, GES and DRSP. However, ERβ had no significant effect on the 
relative agonist potencies of any of the test compounds. Taken together, the results show that 
neither ERα, nor ERβ, is required for progestogen-induced transactivation via PR-B, but that ERβ 
can in fact decrease the maximal responses of all the progestogens, while ERα decreases the 
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Figure 3.3. ERβ decreases the basal transactivational activity of PR-B possibly by reducing the 
expression levels of PR-B, while ERα increases PR-B-mediated basal transactivational activity but 
decreases PR-B expression levels. COS-1 cells were transiently transfected with either 900 ng of the pGL2-
basic empty vector (only A and E) or 900 ng pMT-hPR-B and 9 000 ng of the pTAT-PRE-E1b-luciferase 
promoter-reporter construct, in the absence (900 ng pGL2-basic) or presence of 900 ng of either the pSG5-
hERα or pSG5-hERβ expression vector. The cells were incubated with 0.1% EtOH for 24 hours. (A) Whole 
cell extracts were prepared and protein lysates were subsequently analysed by western blotting with primary 
antibodies specific to PR-A/B, ERα, ERβ and GAPDH. A representative blot is shown. (B-D). Quantification 
of western blots from two independent experiments using the Thermo Scientific My Image Analysis 
software is shown. (E) The basal transcriptional activity of PR-B is expressed relative to the response with 
the empty vector (pGL2-basic) set as 1. (F) The effects of ERα and ERβ on the basal transcriptional activity 
of PR-B are expressed as percentage relative luciferase activity, with the response of PR-B alone (from E) 
set as 100%, and all other conditions set relative to this. The result shown is the average of at least two 
independent experiments with each condition performed in triplicate (± SEM).  
 
3.3. Progestogen-induced upregulation of the c-myc gene in the human T47D 
breast cancer cell line is not modulated in the presence of ERα or ERβ 
antagonists 
Next, we investigated whether the ER subtypes could modulate the progestogen-induced regulation 
of an endogenous PRE-containing gene, c-myc. The human T47D breast cancer cell line was used 
as model system and the western blot in figure 3.5A confirms previous reports that T47D cells 
endogenously express both PR isoforms (Horwitz et al., 1978; Poutanen et al., 1992; Vienonen et 
al., 2001) and both ER subtypes (Horwitz et al. 1978; Keydar et al. 1979). A time-course study was 
performed to evaluate optimal c-myc mRNA expression in the presence of MPA. Considering that 
Giulianelli et al. (2012) measured c-myc mRNA expression in the presence of 10 nM MPA, we 
incubated T47D cells with either 0.1% (v/v) EtOH or 10 nM MPA for 15 min, 30 min, 1 hour, 3 
hours, 6 hours, 12 hours and 24 hours. RNA isolation, cDNA synthesis and qPCR were 
subsequently performed and results show maximal MPA-induced mRNA expression at 24 hours 
(figure 3.5B). 





 PR-B PR + ERα PR + ERβ 
MAX (%) ± SEM 100 ± 0.0 17.18 ± 3.96 36.37 ± 8.30 
EC50 (M) ± SEM 6.97 × 10
-11





PR-B PR + ERα PR + ERβ   PR-B PR + ERα PR + ERβ 
MAX (%) ± SEM 100 ± 0.0 33.62 ± 5.01 34.72 ± 3.26  MAX (%) ± SEM 100 ± 0.0 31.37 ± 7.50 40.12 ± 8.49 
EC50 (M) ± SEM 1.36 × 10
-10
 ± 0.28 1.78 × 10
-9  
± 0.99 1.44 × 10
-10  
± 0.17  EC50 (M) ± SEM 2.65 × 10
-12
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PR-B PR + ERα PR + ERβ   PR-B PR + ERα PR + ERβ 
MAX (%) ± SEM 100 ± 0.0 18.89 ± 7.20 33.17 ± 6.63  MAX (%) ± SEM 100 ± 0.0 29.83 ± 10.23 35.25 ± 2.04 
EC50 (M) ± SEM 2.96 × 10
-10
 ± 1.27 1.63 × 10
-10  
± 0.97 1.38 × 10
-10  
± 0.84  EC50 (M) ± SEM 2.45 × 10
-10  
± 1.15   1.00 × 10
-10  





PR-B PR + ERα PR + ERβ   PR-B PR + ERα PR + ERβ 
MAX (%) ± SEM 100 ± 0.0 26.27 ± 9.04 45.50 ± 3.52  MAX (%) ± SEM 100 ± 0.0 27.25 ± 12.79 43.19 ± 18.34 
EC50 (M) ± SEM 3.61 × 10
-11 
± 1.55   2.52 × 10
-11  
± 1.10 1.93 × 10
-11  
± 0.37  EC50 (M) ± SEM 1.36 × 10
-9
 ± 0.77 4.68 × 10
-9  
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Figure 3.4. ERα and ERβ decrease the PR-B-mediated efficacies of all progestogens tested, while the 
relative agonist potency of only Prog is decreased by ERα. COS-1 cells were transiently transfected with 
900 ng of the pMT-hPR-B expression vector and 9 000 ng of the pTAT-PRE-E1b-luciferase promoter-
reporter construct, in the absence (900 ng pGL2-basic) and presence of 900 ng of either the pSG5-hERα or 
pSG5-hERβ expression vector. The cells were subsequently incubated with increasing concentrations of  
(A) R5020 (♦), (B) Prog (●), (C) bProg (□), (D) NET-A (■), (E) LNG (▼), (F) GES (◊) and (G) DRSP (*) 
for 24 hours. Induction is shown as relative luciferase activity with PR-B in the presence of 0.1% EtOH set 
as 1, and all other responses set relative to this. Result shown is the average of at least two independent 
experiments, with each condition performed in triplicate ( SEM). Data were analysed to obtain the relative 
maximal response (MAX) ± SEM and EC50 ± SEM values for PR-B or PR-B in the presence of ERα (PR-B 
+ ERα) or ERβ (PR-B + ERβ), respectively. MAX of each test compound via PR-B alone was set as 100%, 
and the MAX of each test compound via PR-B in the presence of ERα or ERβ calculated relative to this. 
Statistical analysis of the MAX values indicated the following: PR-B vs. PR-B + ERα: R5020, Prog and 
NET-A (p<0.001); bProg, LNG and DRSP (p<0.01); GES (p<0.05); and PR-B vs. PR-B + ERβ: Prog, NET-
A and LNG (p<0.001); R5020, bProg and GES (p<0.01); DRSP (p<0.05). Statistical analysis of the EC50 
values indicated the following: PR-B vs. PR-B + ERα: Prog (p<0.05); R5020, bProg, NET-A, LNG, GES 
and DRSP (p>0.05); and PR-B vs. PR-B + ERβ: R5020, Prog, bProg, NET-A, LNG, GES, DRSP (p>0.05). 
 
T47D cells were next treated for 24 hours with either 0.1% (v/v) EtOH or 1 nM of the progestogens, 
in the absence and presence of 10 µM of the ERα- or ERβ-specific antagonists, MPP (Sun et al. 
2002) and PHTPP (Aguirre et al. 2010), respectively. The concentration of 1 nM progestogen was 
chosen as the serum concentrations of at least three progestins, MPA, NET and DRSP, in 
contraceptive users have previously been reported to be in the nanomolar range (reviewed in 
Africander, et al. 2011a; Blode et al. 2012; Ito et al. 2016). We did not include bProg in these 
experiments as we showed that Prog and bProg displayed similar PR-B-mediated effects at 1 nM on 
a simple synthetic PRE-containing promoter (figure 3.1A). Figure 3.6A shows that all the 
progestogens, except R5020, upregulated the mRNA expression of the c-myc gene. Although 
inductions of more than 100-fold were observed, statistical analysis indicated that c-myc gene 
expression was not significantly upregulated by any of the progestogens.  
Next we set out to determine whether the ERα- or ERβ-specific antagonists MPP and PHTPP, 
respectively, could modulate progestogen-induced c-myc mRNA expression. Notably, R5020 was 
excluded from any further analysis as no induction was obtained with this ligand. In addition, 
results for LNG in the presence of the ER antagonists are not shown as these samples could not be 
detected. Results in figure 3.6B and 3.6C show that both MPP and PHTPP appeared to increase c-
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myc mRNA expression. Furthermore, neither MPP nor PHTPP had a significant effect on Prog-, 













































Figure 3.5. (A) Both PR isoforms and ER subtypes are expressed in the T47D breast cancer cell line. 
Whole cell extracts were prepared from the T47D cell line. Untransfected COS-1 cells were used as the 
negative control (-ve), while COS-1 cells transfected with expression vectors for PR-A, PR-B, ERα or ERβ 
respectively, were used as positive controls (+ve). Protein lysates were analysed by western blotting with 
primary antibodies specific to PR-A/B, ERα, ERβ and GAPDH. A representative blot is shown. (B) Time-
course analysis showing optimal MPA-induced c-myc mRNA expression at 24 hours. T47D cells were 
treated with either 0.1% EtOH (vehicle control) or 10 nM MPA for 15 min, 30 min, 1 hour, 3 hours, 6 hours, 
12 hours and 24 hours. Total RNA was isolated and reverse transcribed. Relative c-myc mRNA expression 
was measured by realtime qPCR analysis and normalised to GAPDH mRNA expression. Results are 
expressed as a ratio of c-myc/GAPDH expression with 0.1% EtOH set as 1. The result shown is from a 
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Figure 3.6. MPP and PHTPP do not influence the upregulation of c-myc mRNA expression in response 
to the progestogens. T47D breast cancer cells were incubated for 24 hours with either 0.1% EtOH (vehicle 
control) or 1 nM of each of the test compounds in the (A) absence and (B and C) presence of the receptor 
specific antagonists for (B) ERα (MPP) or (C) ERβ (PHTPP). Total RNA was isolated and reverse 
transcribed. Relative c-myc mRNA expression was measured by realtime qPCR and normalised to GAPDH 
mRNA expression. Results are expressed as a ratio of c-myc/GAPDH expression with 0.1% EtOH set as 1. 
The result shown is from a single experiment performed in duplicate.  
 
3.4. Progestogens display similar relative agonist efficacies for transrepression 
via PR-B, while appearing to display differential agonist potencies  
The PR regulates gene expression by either increasing (transactivation) or decreasing 
(transrepression) transcription of target genes (Griekspoor 2007; Kalkhoven et al. 1996; Kobayashi 
et al. 2010). Having shown that progestins mostly display similar progestogenic activity for 
transactivation via PR-B, we next evaluated the progestogenic properties for PR-B-mediated 
transrepression. The COS-1 cell line was transiently transfected with the pMT-hPR-B expression 
vector, a luciferase reporter plasmid linked downstream to five copies of a NFĸB site (5xNFκB-
luciferase) and the pGL2-basic empty vector to a total amount of 6 μg DNA (previously optimised 
in the Africander laboratory). The cells were subsequently incubated with 0.1% (v/v) EtOH in the 
absence and presence of 2.0 ng/ml TNFα, or 2.0 ng/ml TNFα in the presence of increasing 
concentrations of the test compounds for 24 hours. As shown in figure 3.7A, treatment with TNFα 
resulted in a 12-fold induction on the synthetic 5xNFκB promoter-reporter construct. The results in 
figure 3.7B and Table 3.2 clearly show that Prog and bProg display similar agonist efficacies to 
each other and the PR-selective agonist R5020 for transrepression via PR-B. Furthermore, bProg 
was shown to be equally potent to R5020 at repressing the TNFα-induced response. Although it 
appeared that Prog was less potent than both R5020 and bProg, this difference was surprisingly not 
statistically significant. Results in 3.7C showed similar maximal repression of the TNFα-induced 
response by MPA, NET-A, LNG GES, and DRSP and that the percentage repression observed by 
the progestins was not significantly different from R5020, Prog and bProg (figure 3.7B; Table 3.2). 
In terms of relative agonist potencies, R5020, bProg, NET-A, LNG, GES and DRSP were equally 
D C 
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potent to each other and Prog, while MPA was significantly less potent than all these progestogens 
with the exception of Prog. 
3.5. Both ER subtypes can modulate the PR-B-mediated transrepressive 
activities of some progestogens 
Having shown that all the progestogens displayed similar maximal repression on the NFĸB 
promoter-reporter construct via PR-B, whilst appearing to display differential agonist potencies, and 
that the ER subtypes significantly decreased the PR-B-mediated maximal responses of most 
progestogens for transactivation, we next evaluated whether ERα and/or ERβ could modulate the 
PR-B-mediated relative agonist efficacies and potencies of the test compounds for transrepression. 
The COS-1 cell line was transiently transfected with the pMT-hPR-B cDNA expression vector and 
the 5xNFκB-luciferase promoter-reporter construct, in the absence (pGL2-basic empty vector) and 
presence of an expression vector for either pSG5-hERα or pSG5-hERβ. The cells were 
subsequently treated as in Section 3.4.  
Results showed that the presence of ERα did not significantly affect the relative agonist efficacies 
of Prog (figure 3.8C), bProg (figure 3.8D), MPA (figure 3.8B) and NET-A (figure 3.8E) for 
transrepression via PR-B, while completely abolishing the PR-B-mediated transrepressive activities 
of R5020 (figure 3.8A) and the newer generation progestins, LNG (figure 3.8F), GES (figure 3.8G) 
and DRSP (figure 3.8H). Furthermore, although it appeared as though the PR-B-mediated relative 
agonist potencies of bProg (figure 3.8D) and NET-A (figure 3.8E) on the NFκB-containing 
promoter-reporter construct increased in the presence of ERα, only the increased potencies of Prog 
(figure 3.8C) and MPA (figure 3.8B) were significantly different (p<0.05).    
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Figure 3.7. Transrepression activity of Prog, bProg and select progestins from different generations 
via PR-B. COS-1 cells were transiently transfected with 1 500 ng of the pMT-hPR-B expression vector, 3 
000 ng of the 5xNFκB-luciferase promoter-reporter construct and 1 500 ng of the pGL2-basic empty vector. 
Cells were treated with (A) 0.1% EtOH in the absence and presence of 2.0 ng/ml TNFα, or (B) 2.0 ng/ml 
TNFα in the presence of increasing concentrations of R5020 (♦), Prog (●) and bProg (□), or (C) 2.0 ng/ml 
TNFα in the presence of increasing concentrations of R5020 (♦), Prog (●), MPA (▲), NET-A (■), LNG 
(▼), GES (◊) and DRSP (*) for 24 hours. (A) TNFα induction was plotted relative to 0.1% EtOH alone set 
as 1. (B and C) TNFα-induction in (A) was set as 100%, and the repression by each test compound was set 
relative to this.  The result shown is the average of at least two independent experiments with each condition 
performed in triplicate (± SEM).   
 
Table 3.2. Relative agonist efficacies (maximal repression (MAX) in %) and potencies (expressed as 
EC50 in M) of the test compounds for transrepression via PR-B.
b 
Test compounds Classification MAX (%) ± SEM EC50 (M) ± SEM 
R5020 PR-selective agonist 100.00 ± 0.0 1.64 × 10
-12
 ± 0.81 
Prog Natural progestogen 101.60 ± 2.10 5.39 × 10
-10




84.81 ± 16.43 2.65 × 10
-12






99.85 ± 15.45 3.63 × 10
-9
 ± 3.20 









115.70 ± 7.73 2.18 × 10
-12






105.80 ± 17.15 2.62 × 10
-12






75.67 ± 12.52 5.11 × 10
-10
 ± 5.08 
  b
Data depicted in figure 3.7B and 3.7C were analysed and the relative maximal repression (MAX) ± SEM and 
EC50 ± SEM values were obtained. MAX values for all test compounds are expressed as a percentage of the 
R5020 response (set as 100% repression). Statistical analysis of the MAX values indicated R5020 vs. Prog 
vs. bProg vs. MPA vs. NET-A vs. LNG vs. GES vs. DRSP (p>0.05). Statistical analysis of the EC50 values 
indicated that R5020 vs. Prog vs. bProg vs. NET-A vs. LNG vs. GES vs. DRSP (p>0.05); R5020 vs. MPA 
(p<0.05); Prog vs. bProg, MPA, NET-A, LNG, GES, DRSP (p>0.05); MPA vs. LNG and GES (p<0.05); 
MPA vs. NET-A vs. DRSP (p>0.05); NET-A vs. LNG vs. GES vs. DRSP (p>0.05); bProg vs. MPA 
(p<0.05); bProg vs. NET-A, LNG, GES and DRSP (p>0.05). 
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Considering that R5020, LNG, GES and DRSP were unable to repress the TNFα-induced response 
on the synthetic NFκB-containing promoter in the presence of ERα, relative agonist efficacies and 
potencies could not be determined for these compounds. In contrast to ERα, ERβ had no significant 
effect on the relative efficacies of any of the progestogens investigated in this study, while 
significantly increasing the potencies of Prog and MPA. Although ERβ also appeared to increase 
the potencies of R5020, NET-A and DRSP, it was surprisingly not statistically significant. 
3.6. ERβ, but not ERα, appears to modulate Prog-, MPA-, NET-A-, LNG-, 
GES- and DRSP-induced repression of IL-8 gene expression 
Having shown that ERα, but not ERβ, modulates the PR-B-mediated transrepressive efficacies of 
R5020, LNG, GES and DRSP on a simple synthetic NFκB-containing promoter, whilst the 
potencies of Prog and MPA were shown to be significantly increased in the presence of both ER 
subtypes, we were interested in investigating whether the ER subtypes could also modulate the 
progestogenic properties for transrepression on an endogenous NFκB-containing promoter. First, 
we determined the optimal time for TNFα-induced expression of the endogenous IL-8 gene in the 
human T47D breast cancer cell line. Cells were incubated with 0.1% (v/v) EtOH in the absence and 
presence of 20.0 ng/ml TNFα for 30 min, 2 hours, 6 hours and 24 hours. It should be noted that the 
concentration of TNFα used for realtime qPCR is higher than that used in the promoter-reporter 
assays as this concentration has previously been reported to significantly induce the expression of 
endogenous cytokine genes (Africander, et al. 2011b; Verhoog et al. 2011; Louw-du Toit et al. 
2014). Results in figure 3.9 showed that TNFα upregulated IL-8 mRNA expression at 30 min, 6 
hours and 24 hours, with optimal induction observed at 6 hours (23.3-fold).  




 PR-B PR+ ERα PR+ ERβ   PR-B PR+ ERα PR+ ERβ 
MAX (%) ± SEM 100.00 ± 0.0 ND 91.43 ± 6.92  MAX (%) ± SEM 100.00 ± 0.0 113.60 ± 8.06 111.00 ± 32.95 
EC50 (M) ± SEM 1.64 × 10
-12
 ± 0.81  ND 1.20 × 10
-13
 ± 0.70  EC50 (M) ± SEM 3.63 × 10
-9
 ± 3.20 1.25 × 10
-13 
± 0.88 1.53× 10
-13







 PR-B PR+ ERα PR+ ERβ   PR-B PR+ ERα PR+ ERβ 
MAX (%) ± SEM 100.00 ± 0.0 92.46 ± 7.96 102.7 ± 14.74  MAX (%) ± SEM 100.00 ± 0.0 107.6 ± 37.10 108.3 ± 22.36 
EC50 (M) ± SEM 5.39 × 10
-10
 ± 4.69  1.91 × 10
-13
 ± 0.75 3.66 × 10
-13
 ± 0.22  EC50 (M) ± SEM 2.65 × 10
-12
 ± 2.62 3.03 × 10
-13
 ± 2.79 1.58 × 10
-12
 ± 1.54 
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PR-B PR+ ERα PR+ ERβ   PR-B PR+ ERα PR+ ERβ 
MAX (%) ± SEM 100.00 ± 0.0 108.90 ± 25.59 120.00 ± 30.43  MAX (%) ± SEM 100.00 ± 0.0 ND 97.03 ± 3.23 
EC50 (M) ± SEM 1.33 × 10
-11
 ± 1.28 1.90 × 10
-12
 ± 1.34 1.91 × 10
-12
 ± 0.72  EC50 (M) ± SEM 2.18 × 10
-12
 ± 0.72 ND 1.51 × 10
-12




 PR-B PR+ ERα PR+ ERβ   PR-B PR+ ERα PR+ ERβ 
MAX (%) ± SEM 100.00 ± 0.0 ND 102.3 ± 12.80  MAX (%) ± SEM 100.00 ± 0.0 ND 88.74 ± 9.22 
EC50 (M) ± SEM 2.62 × 10
-12
 ± 1.29 ND 2.83 × 10
-13
 ± 0.77  EC50 (M) ± SEM 5.11 × 10
-10
 ± 5.08 ND 2.49 × 10
-13
 ± 1.06 
 
Figure 3.9 legend on next page. 
E F 
H G DRSP GES 
NET-A LNG 




































































































































































































Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
66 
 
Figure 3.8. ERα, but not ERβ, abolishes the agonist efficacies and potencies of R5020, LNG, GES and 
DRSP for transrepression via PR-B. COS-1 cells were transiently transfected with 1 500 ng of the pMT-
hPR-B expression vector and 3 000 ng of the 5xNFκB-luciferase promoter-reporter construct, in the absence 
(1 500 ng pGL2-basic) and presence of 1 500 ng of either the pSG5-hERα or pSG5-hERβ expression vector. 
Cells were treated with 0.1% EtOH in the absence and presence of 2.0 ng/ml TNFα, or (B) 2.0 ng/ml TNFα 
in the presence of increasing concentrations of (A) R5020 (♦), (B) MPA (▲), (C) Prog (●), (D) bProg (□),  
(E) NET-A (■), (F) LNG (▼), (G) GES (◊) and (H) DRSP (*) for 24 hours. TNFα-induction (from figure 
3.7A) was set as 100%, and the repression by each test compound was set relative to this. The result shown is 
the average of at least two independent experiments with each condition performed in triplicate (± SEM). 
Relative maximal repression (MAX) ± SEM and EC50 ± SEM values were obtained. MAX values indicated 
in the tables for all test compounds are expressed as a percentage, with the maximal repression obtained for 
each test compound via PR-B set as 100%, and maximal repression for PR-B in the presence of either ERα 
or ERβ set relative to this. ND denotes that the value could not be determined using non-linear regression 
and sigmoidal dose response analysis. Statistical analysis of the MAX values indicated the following: PR-B 
vs. PR-B + ERα: Prog, bProg, MPA and NET-A (p>0.05), and PR-B vs. PR-B + ERβ: R5020, Prog, bProg, 
MPA, NET-A, LNG, GES and DRSP (p>0.05). Statistical analysis of the EC50 values indicated the 
following: PR-B vs. PR-B + ERα: Prog and MPA (p<0.05); bProg and NET-A (p>0.05), and PR-B vs. PR-B 











































Figure 3.9. Optimal TNFα-induced expression of the endogenous IL-8 gene in the T47D cell line occurs 
at 6 hours. T47D cells were incubated with either 0.1% EtOH (vehicle control) or stimulated with 20.0 
ng/ml TNFα for 30 min, 2 hours, 6 hours and 24 hours. Total RNA was isolated and reverse transcribed. 
Relative IL-8 mRNA expression was measured by realtime qPCR and normalised to GAPDH mRNA 
expression. Results are expressed as a ratio of IL-8/GAPDH expression with 0.1% EtOH set as 1. The result 
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To compare the effects of the progestogens on IL-8 mRNA expression in the human T47D cell line, 
and to determine how these effects may be modulated by either ERα or ERβ, cells were 
subsequently treated for 6 hours with 0.1% (v/v) EtOH in the absence and presence of 20.0 ng/ml 
TNFα, or 20.0 ng/ml TNFα and 1 nM of the progestogens, in the absence and presence of 10 µM of 
the ERα- and ERβ-selective antagonists, MPP and PHTPP, respectively. Results in figure 3.10A 
showed a ~26-fold increase in IL-8 mRNA expression in the presence of TNFα. As shown in figure 
3.10B, Prog, NET-A, LNG, GES and DRSP significantly repressed TNFα-induced IL-8 gene 
expression. Even though MPA appeared to repress TNFα-induced IL-8 gene expression to a lesser 
extent than the other progestogens, this difference was not statistically significant and probably due 
to large experimental error. 
We next determined whether the ERα- and/or ERβ-specific antagonists could modulate the 
progestogen-induced repression of IL-8 gene expression. Results in figure 3.10C show that the 
ERα-specific antagonist (MPP) had no significant effect on the progestogen-induced repression of 
IL-8 mRNA expression. Although we could not obtain statistical significance in this single 
experiment, the ERβ-specific antagonist (PHTPP) appeared to completely abolish repression of IL-
8 gene expression by all progestogens, except R5020 (figure 3.10D). Surprisingly, MPP 
significantly repressed TNFα-induced IL-8 gene expression (figure 3.10C), while PHTPP did not 
affect the expression (figure 3.10D). 
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Figure 3.10. The ERα-specific antagonist, MPP, has no effect on progestogen-induced repression of IL-
8 gene expression, while it appears to abolished by the ERβ-specific antagonist, PHTPP. T47D breast 
cancer cells were incubated with (A) 0.1% EtOH (vehicle control) in the absence and presence of 20.0 ng/ml 
TNFα, or (B) 20.0 ng/ml TNFα in the absence and presence of 1 nM of each test compound or (B) in the 
presence of the (C) ERα-specific antagonist MPP, and (D) ERβ-specific antagonist PHTPP for 6 hours. Total 
RNA was isolated and reverse transcribed. Relative IL-8 mRNA expression was measured by realtime qPCR 
analysis and normalised to GAPDH mRNA expression. Results are expressed as a ratio of IL-8/GAPDH 
expression with (A) 0.1% EtOH set as 1 or (B, C and D) TNFα induction in (A) set as 100% and the 
repression by each test compound in the absence and presence of MPP or PHTPP set  relative to this. 
 
3.7. R5020, MPA, LNG and GES are the most potent agonists for proliferation  
of theT47D breast cancer cell line 
Having shown that all progestogens can activate and repress gene expression in the presence of 
overexpressed PR-B, and knowing that both transactivation and transrepression of genes contribute 
to the phenotype of cell proliferation (Moore et al. 1997; Kalkhoven et al. 1996), we next wanted to 
compare the relative agonist efficacies and potencies of the different progestogens for proliferation 
via PR-B. However, we were unable to optimise proliferation assays in the PR- and ER-negative 
MDA-MB-231 breast cancer cell line (Horwitz et al. 1978; Leo et al. 2004) transfected with the 
pMT-hPR-B expression vector. We thus evaluated the proliferative effects of the progestogens in 
the T47D breast cancer cell line endogenously expressing the PR isoforms and ER subtypes using 
the MTT assay. The cells were treated with either 0.1% (v/v) EtOH or increasing concentrations of 
the test compounds for 72 hours. Results in figure 3.11A, 3.11B and Table 3.3 show that Prog, 
bProg, MPA, LNG, GES and DRSP displayed similar proliferative efficacies to each other and the 
PR-specific agonist, R5020. While NET-A appeared to be more efficacious than all the other 
progestogens, statistically significant differences could only be determined for NET-A vs. bProg 
and NET-A vs. DRSP. In terms of potencies, Prog and bProg displayed similar potencies to each 
other, but were significantly less potent than R5020 (figure 3.11A). Results also indicated that 
MPA, LNG and GES displayed similar potencies to each other and to R5020, while NET-A and 
DRSP were less potent than R5020, MPA, LNG and GES. Furthermore, MPA and GES were 
significantly more potent than bProg but not Prog. Although NET-A was more efficacious than 
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DRSP, these two progestins displayed similar potencies to each other. In summary, all the 
progestogens investigated in this study, except NET-A and DRSP, displayed similar proliferative 
efficacies and potencies. 


























































Figure 3.11. (A) Prog and bProg display similar proliferative efficacies and potencies to each other. 
T47D breast cancer cells were incubated with either 0.1% EtOH or increasing concentrations of  
R5020 (♦), Prog (●) or bProg (□) for 72 hours. (B) All progestogens, except NET-A and DRSP, display 
similar proliferative maximal responses and relative agonist potencies. T47D breast cancer cells were 
incubated with either 0.1% EtOH or increasing concentrations of R5020 (♦), Prog (●), MPA (▲), NET-A 
(■), LNG (▼), GES (◊) or DRSP (*) for 72 hours. (A and B) Four hours before the 72 hour incubation 
period lapsed, MTT solution was added and the cells incubated for a further 4 hours. Absorbances were 
measured at 550 nm and proliferation is shown as fold induction with 0.1% EtOH set as 1. The result shown 
is the average of at least two independent experiments with each condition performed in triplicate (± SEM).  
A 
B 
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Table 3.3. Relative efficacies (maximal response (MAX) in %) and potencies (expressed as EC50 in M) 
of the test compounds for proliferation.
c
  
Ligand Classification MAX (%) ± SEM EC50 (M) ± SEM 
R5020 PR-selective agonist 100.00 ± 0.0 1.10 × 10
-11
 ± 0.11 
Prog Natural progestogen 95.09 ± 0.59 3.00 × 10
-10




90.41 ± 1.39 5.93 × 10
-10






99.87 ± 0.93 3.71 × 10
-11
 ± 2.50 
NET-A 112.3 ± 3.84 3.95 × 10
-9





progestin 97.23 ± 5.80 
8.07 × 10
-11





progestin 102.6 ± 5.56 
3.09 × 10
-11





progestin 89.60 ± 2.45 
1.15 × 10
-9
 ± 0.43 
      c
Data shown in figure 3.11A and 3.11B were analysed to obtain relative maximal response (MAX) ± SEM 
and EC50 ± SEM values for each of the test compounds. MAX values are expressed as a percentage relative 
to 10
-5
 M R5020 = 100% and statistical analysis of the MAX values indicated that R5020 vs. Prog vs. bProg 
vs. MPA vs. LNG vs. GES vs. DRSP (p>0.05); NET-A vs. Prog, MPA, LNG and GES (p>0.05); NET-A vs. 
bProg and DRSP (p<0.05). Statistical analysis of the EC50 values indicated that R5020 vs. MPA vs. LNG vs. 
GES (p>0.05); R5020 vs. Prog (p<0.05); R5020 vs. bProg and DRSP (p<0.01); R5020 vs. NET-A 
(p<0.001); Prog vs. bProg, MPA, NET-A, LNG, GES and DRSP (p>0.05); MPA vs. NET-A (p<0.01); MPA 
vs. DRSP (p<0.05); NET-A vs. GES (p<0.001); NET-A vs. LNG (p<0.01); NET-A vs. DRSP (p>0.05); 
LNG vs. DRSP (p<0.05); GES vs. DRSP (p<0.01); bProg vs. NET-A, LNG and DRSP (p>0.05); bProg vs. 
MPA and GES (p<0.05).  
 
3.8. ERα- and ERβ-specific antagonists do not modulate progestogen-induced 
proliferation of the T47D breast cancer cells 
Having shown that neither the ERα-specific antagonist (MPP) nor the ERβ-specific antagonist 
(PHTPP) modulated the progestogen-induced upregulation of c-myc gene expression, while the 
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progestogen-induced downregulation of IL-8 gene expression appears to completely reversed by 
PHTPP, but not MPP, we next investigated whether the ER specific antagonists could modulate the 
progestogen-induced proliferation of the T47D breast cancer cell line. T47D cells were thus treated 
with 0.1% (v/v) EtOH or 1 nM test compound in the absence and presence of 10 µM MPP or 
PHTPP, and cell proliferation quantified using the MTT assay. As shown in figure 3.12A and 3.12B 
all the progestogens could induce proliferation of the T47D breast cancer cells at 1 nM, albeit to 
different extents. Furthermore, although the result in figure 3.12A show that cell proliferation 
induced by the progestogens was increased in the presence of MPP, this is probably not an increase 
in progestogen-induced proliferation, but rather due to the fact that MPP itself increases 
proliferation. In contrast, PHTPP itself had no effect on proliferation and increased LNG- and GES-
induced breast cancer cell proliferation (figure 3.12B).  
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Figure 3.12. The ERα-specific antagonist, MPP, has no effect on progestogen-induced breast cancer 
cell proliferation, while LNG- and GES-induced breast cancer cell proliferation is significantly 
increased by the ERβ-specific antagonist, PHTPP. T47D breast cancer cells were incubated with (A and 
B) 0.1% EtOH (vehicle control) or 1 nM of the test compounds in the absence and presence of 10 µM of the 
receptor specific antagonists for (A) ERα (MPP) or (B) ERβ (PHTPP) for 72 hours. (A and B) Four hours 
before the 72 hour incubation period lapsed, MTT solution was added and the cells were incubated for a 
further 4 hours. Absorbances were measured at 550 nm and proliferation is shown as fold induction with 
0.1% EtOH set as 1. The result shown is the average of at least two independent experiments with each 

































A wide variety of progestins are extensively used in various therapeutic applications, including 
HRT (Whitehead et al. 1979; Greendale et al. 1999; Hickey et al. 2005) and contraception (Sitruk-
Ware 2005a; Sitruk-Ware & Nath 2010; Africander, et al. 2011a). Progestins can be classified into 
four consecutive generations (Sitruk-Ware 2004a), with the first two generations often referred to as 
the older progestins, while the third and fourth generations are considered the newer progestins 
(Sitruk-Ware 2004a; Sitruk-Ware & Plu-Bureau 2004). These newer progestins were designed to be 
more specific for the PR (Sitruk-Ware 2004a) and more closely mimic the biological effects of Prog 
(Sitruk-Ware 2006). Evidence from several clinical trials, population-based case control studies and 
experimental studies suggest an association between the use of some of the older generation 
progestins like MPA, NET-A and LNG, and increased risk of developing breast cancer (Lee et al. 
1987; Kalkhoven et al. 1994; Ross et al. 2000; Newcomb et al. 2002; Rossouw et al. 2002; Althuis 
et al. 2003; Beral 2003; Hunter et al. 2010; Li et al. 2012; Giulianelli et al. 2012; Ruan et al. 2012; 
Beaber et al. 2014; Wargon et al. 2014). This has however led to the misconception that all 
progestins increase breast cancer risk, whilst in reality there has been a lack of research 
investigating the association between breast cancer and the use of newer generation progestins. The 
concerns of increased breast cancer risk have however resulted in women searching for safer HRT 
alternatives. The use of compounded bio-identical HRT has thus gained popularity amongst women 
as compounded bio-identical hormones such as bProg, have been claimed to be “safer” than the 
synthetic hormones used in conventional HRT (Boothby et al. 2004; Boothby & Doering 2008; 
Holtorf 2009; Panay & Fenton 2010; Files et al. 2011). However, these claims have not been 
substantiated by scientific evidence. 
Progestins, natural Prog and bProg (progestogens) exert their biological effects by binding to PRs 
(Conneely et al. 2001; Conneely et al. 2003), namely PR-A and PR-B (Kastner et al. 1990), with 
PR-B being the more transcriptionally active isoform in the presence of ligand and the more 
proliferative PR isoform in breast cancer (Conneely et al. 2003; Diep et al. 2015). Surprisingly, 
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even though progestins are PR ligands, comparative agonist efficacy and potency values for 
progestins for transactivation and transrepression via PR-B is lacking. Furthermore, emerging 
evidence suggests that crosstalk between PR and ERα signalling pathways plays an important role 
in breast cancer, and may be a potential mechanism whereby MPA increases breast cancer risk. 
This thus raised the question of whether ERα is required for PR-B-mediated gene regulation and 
breast cancer cell proliferation induced by other progestogens. Given that the ER exists as two 
subtypes, ERα and ERβ, a further question was whether ERβ would also be needed for 
progestogen-induced gene regulation via PR-B. In the light of the above, in Chapter 3 we thus 
pharmacologically characterised the progestogens in terms of their efficacies and potencies for 
transactivation and transrepression via PR-B on synthetic promoters containing PRE and NFκB 
binding sites, respectively, while also evaluating the progestogen-induced transactivation and 
transrepression of endogenous PRE- and NFκB-containing promoters. We also determined the 
efficacies and potencies of the progestogens for proliferation of the T47D breast cancer cell line. 
Subsequently, we investigated whether ERα and/or ERβ modulates progestogen-induced gene 
regulation and cell proliferation. 
4.2. Most progestogens are agonists for transactivation on both a synthetic and 
endogenous PRE-containing promoter 
In the first part of this thesis (Section 3.1), we aimed to compare the relative agonist efficacy and 
potency (EC50) values of select progestogens for transactivation via PR-B on a synthetic PRE-
containing promoter (figure 3.1; Table 3.1). PR-B was overexpressed in COS-1 cells as these cells 
express negligible amounts of endogenous steroid receptors (Africander et al. 2014), which allowed 
the accurate determination of the transcriptional activity of the test compounds via PR-B. Although 
a number of studies have examined the relative agonist efficacies and potencies of progestogens via 
the PR, these studies often do not distinguish between PR-isoforms or they examine activities in 
cell lines that also express other steroid receptors to which these ligands may bind (Markiewicz & 
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Gurpide 1994; Bray et al. 2005). Our study is thus the first to directly compare the relative agonist 
efficacy and potency values of the progestogens for transactivation via PR-B within the same model 
system. When comparing the relative efficacy values of Prog, bProg and select progestins from 
different generations to the PR-specific agonist R5020 (positive control), we were able to 
characterize the agonist properties of the progestogens. Agonists that display similar, lower or 
higher maximal responses than the positive control, are referred to as full-, partial or supra-agonists, 
respectively (Africander, et al. 2011a). We show that NET-A, LNG, and GES are full PR-B 
agonists, which is in agreement with a previous study showing full agonist activity for these 
progestins in the HeLa cervical carcinoma cell line transfected with PR-B and the PRE-E1b-
chloramphenicol acetyltransferase (CAT) reporter construct (García-Becerra et al. 2004). However, 
in contrast to our findings that Prog and MPA are partial PR-B agonists, Markiewicz and co-
workers (1994) have previously reported full agonist activity for Prog and MPA in T47D cells 
(Markiewicz & Gurpide 1994). It is not surprising that the results differ between these two systems, 
as the T47D cell line endogenously expresses equimolar concentrations of  PR-B and PR-A 
(Horwitz et al. 1978; Keydar et al. 1979; Wargon et al. 2014), and it is likely that these 
progestogens are eliciting their transcriptional effects via both PR-B and PR-A. Considering that the 
newer generation progestins were designed to be more PR specific (Sitruk-Ware 2004a), it was 
surprising that GES and DRSP displayed similar relative agonist efficacies to NET-A and LNG. 
Furthermore, our results also indicate that the two first generation progestins, NET-A and MPA, 
differ in their maximal responses, suggesting that progestins from the same generation will not 
necessarily elicit the same effects.  
In terms of the relative agonist potencies (EC50) of the progestogens via PR-B our results showed 
that there was no significant difference between Prog, R5020, the first (MPA and NET-A) and the 
second (LNG) generation progestins, while the third generation progestin GES was shown to be 
more potent than Prog and the fourth generation progestin DRSP less potent (figure 3.1; Table 3.1). 
The EC50 value of 0.036 nM determined for GES in the present study is similar to the EC50 value of 
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0.018 nM reported by García-Becerra and co-workers (2004) in the HeLa cervical carcinoma cell 
line transfected with PR-B and the PRE-E1b-chloramphenicol acetyltransferase (CAT) reporter 
construct (García-Becerra et al. 2004). Furthermore, the EC50 value of 0.45 nM obtained for MPA 
in our study is in line with that reported by Sasagawa et al. (2008) showing an EC50 value of 0.1 nM 
for MPA in COS-1 cells transfected with PR-B and the PRE2-tk-luciferase reporter (Sasagawa et al. 
2008). 
We next determined whether the progestogens display similar transactivation activities on the 
endogenous c-myc gene which contains a functional PRE sequence in its promoter region (Moore et 
al. 1997), in the T47D breast cancer cell line (figure 3.6A). This cell line was chosen as an in vitro 
model system as it endogenously expresses high levels of the PR isoforms, and is often used to 
study the activity of the PR in breast cancer (Keydar et al. 1979; Wargon et al. 2014). The c-myc 
gene was used as it is overexpressed in many different forms of cancers including breast cancer, 
while the c-myc protein has been shown to regulate a number of genes involved in cellular 
processes such as proliferation, apoptosis, differentiation and cell growth (Liao & Dickson 2000). 
Moreover, c-myc gene expression has previously been shown to be upregulated by the first 
generation progestin MPA (Giulianelli et al. 2012; Wargon et al. 2014). Surprisingly, the results in 
figure 3.6A show that the PR-specific agonist R5020 had no effect on the mRNA expression of c-
myc. In contrast to our results, Moore and co-workers (1997) have previously shown that c-myc 
mRNA expression is upregulated (1.9-fold) by 1 nM R5020 in T47D cells (Moore et al. 1997). 
However, it should be noted that the results in figure 3.6 are representative of a single experiment 
performed in duplicate, and thus the discrepancy between our result for R5020 and that of Moore et 
al. (1997) may simply be ascribed to experimental error on our part. We also showed that Prog, 
MPA, NET-A, LNG, GES and DRSP all appeared to upregulate c-myc mRNA expression (figure 
3.6A). Our results for MPA showing upregulation of c-myc mRNA expression, although not 
statistically significant, is in agreement with results from three previous studies performed in T47D 
cells (Wong & Murphy 1991; Giulianelli et al. 2012; Wargon et al. 2014). Considering that 
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overexpression of the c-myc gene is associated with increased breast cancer cell proliferation, our 
results showing increased expression of the c-myc gene and increased cell proliferation in the 
presence of all the progestogens, except R5020, may suggest that these progestogens promote breast 
cancer via a mechanism involving PR-B. 
4.3. Both ER subtypes decreased the PR-B-mediated maximal responses of all 
the progestogens, except MPA, on a synthetic PRE-containing promoter, while 
ER subtype-specific antagonists have no effect on progestogen-induced 
transactivation of an endogenous PRE-containing promoter 
Giulianelli and co-workers (2012) showed that ERα is required for the PR-B-mediated effects of 
MPA on gene regulation in the MDA-MB-231 breast cancer cell line (Giulianelli et al. 2012), but 
did not investigate the requirement of ERα for any other progestins, or whether ERβ, may also be 
required. Having shown that all progestogens investigated in this study are agonist for 
transactivation via PR-B on a synthetic PRE-containing promoter and that the progestogens 
upregulated the mRNA expression of the endogenous PRE-containing gene, we next determined 
whether the ER subtypes could modulate the progestogen-induced effects. First, we investigated 
whether effects observed by Giulianelli et al. (2012) could be mimicked in our model system and 
results in figure 3.2 show that it could not, as we found that ERα is not required for the MPA-
induced transcriptional activation via PR-B on a synthetic PRE-containing promoter. This 
discrepancy could possibly be attributed to the use of different cell lines and/or promoter reporter 
constructs as we transiently transfected COS-1 cells with PR-B, ERα and the pTAT-2xPRE-E1b-
luciferase promoter-reporter construct, while Giulianelli and co-workers used MDA-MB-231 breast 
cancer cells stably transfected with PR-B, and transiently transfected with ERα as well as a 
(PRE)2pGL3p promoter-reporter construct (Giulianelli et al. 2012). Furthermore, considering that 
the MDA-MB-231 breast cancer cell line, unlike the COS-1 cell line, endogenously express both 
GR (Horwitz et al. 1978) and MR (Leo et al. 2004), and that MPA has previously been shown to 
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bind to both these receptors (Koubovec et al. 2005; Africander et al. 2013), it is possible that the 
GR and/or MR may have contributed to the difference observed between our result and that of 
Giulianelli et al. (2012). Two other factors which may also have contributed to the difference 
between the two studies, could be that the PR-B and ERα protein expression levels vary between 
these two in vitro model systems, or that the transcriptional activity is influenced by co-factors 
which are differentially expressed in different cell lines. Furthermore, we show for the first time 
that ERβ decreased the PR-B-mediated maximal response of MPA (figure 3.2). The exact reason 
for the difference in the effect of ERα and ERβ on the relative maximal response of MPA via PR-B 
is not clear. We speculated that the significant decrease in the maximal responses of MPA in the 
presence of ERβ, but not ERα, may be due to ERβ affecting the expression levels of PR-B. Indeed, 
our results showed that ERβ significantly downregulates PR-B protein levels (figure 3.3A and 
3.3B), while simultaneously decreasing basal PR-B-mediated transcriptional activity (figure 3.3F) 
in COS-1 cells co-expressing PR-B and ERβ. However, to our surprise, ERα also downregulated 
the protein expression levels of PR-B (figure 3.3A and 3.3B), and even more unexpected, this 
decrease in the PR-B protein levels was associated with an increase in the basal PR-B-mediated 
transcriptional activity (figure 3.3F). This does however not explain our results in figure 3.2 
indicating that ERα had no effect on the PR-B-mediated maximal response of MPA. Considering 
that MPA is associated with an increased risk of breast cancer, this result suggests that ERβ may 
protect against MPA-induced breast cancer when co-expressed with PR-B.  
The exact mechanism whereby unliganded ERα downregulates PR-B protein expression whilst also 
increasing basal PR-B-mediated transcriptional activation is unclear, however some speculations 
can be made. PR-B has previously been shown to be activated in the absence of ligand when Ser400 
is phosphorylated by cyclin-dependent protein kinase 2 (CDK2). Considering that increased CDK2 
activity can stimulate PR-B downregulation (Pierson-mullany & Lange 2004), we hypothesize that 
ERα may elevate CDK2 activity, which would lead to the downregulation of PR-B, but also 
increased phosphorylation, and hence activity, of PR-B. To the best of our knowledge, this is the 
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first study to show that ERα upregulates, while ERβ downregulates, the basal transcriptional 
activity of PR-B on a synthetic PRE-containing promoter. Considering that unliganded PR-B can be 
activated through a non-genomic signalling mechanism (Pierson-Mullany et al. 2003; Pierson-
mullany & Lange 2004) and can subsequently activate the expression of PR-regulated genes that 
play a role in cell proliferation (Sartorius et al. 2003; Giulianelli et al. 2012; Wargon et al. 2014), 
our results suggest that ERα may promote PR-positive breast cancer while ERβ may protect against 
it. 
We continued investigating the effects of the ERs on PR-B-mediated agonist efficacies and 
potencies of select progestins from different generations, natural Prog and bProg for transactivation. 
In contrast to the results for MPA, our results showed that ERα significantly lowered the PR-B-
mediated maximal response of R5020, Prog, bProg, NET-A, LNG, GES and DRSP on a synthetic 
PRE-containing promoter, while also decreasing the relative agonist potency of Prog (figure 3.4A-
G). We also show for the first time that ERβ decreased the PR-B-mediated maximal response of all 
the progestogens investigated in this study, including MPA, while having no significant effect on 
the relative agonist potencies of any of the progestogens (figure 3.4A-G). Understanding why ERβ 
would modulate the maximal response of all progestogens, including MPA, while ERα decreased 
the maximal response of all progestogens except MPA is not straightforward. Considering that 
structurally different progestogens can lead to slightly different ligand-receptor conformations 
(Wagner et al. 1996; Rękawiecki et al. 2011; Hapgood et al. 2014), it may be possible that ERβ can 
interact with the MPA-bound conformation of PR-B, while ERα cannot. As mentioned earlier for 
MPA, a limitation of this study was that the effects of the ER subtypes on PR-B protein expression 
was not investigated in the presence of any of the progestogens investigated in the present study. 
We next determined whether the ERα-specific antagonist MPP and/or the ERβ-specific antagonist 
PHTPP, could modulate progestogen-induced upregulation of the c-myc gene. Results showed that 
neither MPP (figure 3.6B) nor PHTPP (figure 3.6C) had any effect on progestogen-induced c-myc 
mRNA expression, suggesting that neither ERα nor ERβ could modulate the progestogen-induced 
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upregulation of the c-myc gene. A major limitation of our study was that we did not use the ER 
antagonist ICI 182 780. This antagonist acts by binding to the ER subtypes and leading to the 
subsequent degradation of the ER subtypes (Alarid et al. 1999; Long & Nephew 2006), while MPP 
and PHTPP exert their effects by binding to ERα and ERβ, respectively, and preventing the ER 
subtypes from activating transcription whilst having no effect on ER protein levels (Hartman et al. 
2009; Chan et al. 2014). Thus, ERα and ERβ are still present in our model system making it 
difficult to ascertain whether the individual ER subtypes would modulate the progestogen-induced 
effects.  
In summary, our results indicating that neither ERα nor ERβ is required for progestogen-induced 
transcriptional activation on a synthetic PRE-containing promoter, and that both MPP and PHTPP 
do not modulate the effects of the progestogens on the endogenous PRE-containing c-myc gene, 
refuted our hypothesis that ERα, but not ERβ, would be required for progestogen-induced gene 
regulation. In fact, we showed that the PR-B-mediated maximal response of all progestogens, 
except MPA, was decreased by the expression of ERα, whereas ERβ decreased the maximal 
response of all the progestogens on the synthetic PRE-containing promoter-reporter construct.  
4.4. All progestogens are agonists for transrepression on both synthetic and 
endogenous NFκB-containing promoters 
Apart from the transactivation mechanism whereby the PR can positively regulate gene expression 
by directly binding to PREs, the PR can also negatively regulate gene expression by repressing the 
activity of the transcription factor NFκB (Kalkhoven et al. 1996; Kobayashi et al. 2010). NFκB 
plays an integral role in the inflammatory response and cell proliferation by regulating the 
expression of pro-inflammatory genes (Ben-Neriah & Karin 2011; Niu et al. 2012). An increase in 
pro-inflammatory gene expression leads to inflammation, and while acute inflammation is 
considered beneficial in that it is a natural mechanism used by the body to fight infection (Ben-
Neriah & Karin 2011), continual expression of high levels of pro-inflammatory genes could lead to 
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chronic inflammation. Chronic inflammation has been shown to be a major etiologic factor in 
promoting breast cancer development and progression, as it contributes to proliferation, 
angiogenesis, metastasis and reduces responsiveness to cancer treatments (Colotta et al. 2009; Culig 
2011; Niu et al. 2012). We investigated the potential PR-mediated anti-inflammatory effects of the 
progestogens, by determining the potential of the progestogens to repress TNFα-induced 
transcription. Specifically, the transrepressive properties of the progestogens via overexpressed PR-
B were investigated on a synthetic NFκB-containing promoter in COS-1 cells, while transrepressive 
properties were also investigated on an endogenous NFκB-containing promoter in T47D cells 
endogenously expressing both PR isoforms. This study is the first to directly compare the relative 
agonist efficacies and potencies for transrepression of R5020, Prog, bProg and select progestins 
from different generations via PR-B. While all progestogens displayed similar relative maximal 
repression to each other and Prog, differences were observed between the potencies of the first 
(MPA), second (LNG) and third (GES) generation progestins (figure 3.7B and 3.7C; Table 3.2).  
To investigate the potential of the progestogens to repress TNFα-induced transcriptional activation 
on an endogenous NFκB-containing promoter, we determined the effects of the different 
progestogens on the expression of the endogenous IL-8 gene in the T47D breast cancer cell line. 
The IL-8 gene was selected as it contains a NFκB binding site in its promoter (Roebuck 1999) and 
has been shown to promote angiogenesis in various different forms of cancer which in turn may 
increase the risk of metastasis (Xie 2001; Benoy et al. 2004; Lin et al. 2004). Furthermore, patients 
with metastatic breast cancers have also been shown to express elevated IL-8 serum levels (Xie 
2001; Benoy et al. 2004). Results from the current study showed that 1 nM R5020 significantly 
downregulates TNFα-induced IL-8 gene expression, which is consistent with the findings of a study 
by Kobayashi and co-workers (2010) showing that 10 nM R5020 downregulated IL-1β-induced IL-
8 gene expression in T47D cells engineered to express either PR-A or PR-B alone (Kobayashi et al. 
2010). Interestingly, all progestogens except MPA significantly repressed TNFα-induced IL-8 
mRNA expression (figure 3.11B). However, it should be noted that these results, like those for c-
Stellenbosch University  https://scholar.sun.ac.za
84 
 
myc mRNA expression (figure 3.6A), were from a single experiment, and thus no definitive 
conclusions can be drawn at this time. 
Taken together, our results show for the first time that all the progestogens investigated in this study 
are full PR-B-agonists for transrepression, and the progestins display differential transrepressive 
potencies on a synthetic NFκB-containing promoter via PR-B. Although the progestogens could 
also repress gene expression on the endogenous NFκB-containing promoter of the IL-8 gene, we 
did not establish which PR isoform is involved in the progestogen-induced effects on endogenous 
IL-8 gene expression, and can therefore not specifically pinpoint the effects to PR-B. 
4.5. Both ERα and ERβ modulate progestogen-induced transcriptional 
repression on a synthetic NFκB-containing promoter, while the ERβ-specific 
antagonist PHTPP appeared to modulate progestogen-induced repression on the 
endogenous NFκB-containing IL-8 gene promoter  
Having shown that all progestogens repress TNFα-induced transcriptional activation on a synthetic 
NFκB-containing promoter via PR-B, we next investigated whether ERα and/or ERβ could 
influence the progestogen-induced transcriptional repression. Interestingly, we showed that ERα 
prevented the ability of the PR-specific agonist R5020, as well as the second (LNG), third (GES) 
and fourth (DRSP) generation progestins to repress gene expression via PR-B, while both ERα and 
ERβ modulated the PR-B-mediated agonist potencies of the natural progestogen Prog and the first 
generation progestin MPA (figure 3.9). These results suggest that ERα may promote inflammation-
induced breast cancer by inhibiting the PR-B-mediated anti-inflammatory effects of R5020, LNG, 
GES and DRSP. In trying to understand the mechanism whereby ERα abolishes the transrepressive 
effects of some, but not all progestogens, it can be speculated that R5020, LNG, GES and DRSP 
induce a conformational change in PR-B which allows ERα to interact with the progestogen-bound 
PR-B, thereby preventing PR-B from interacting with NFκB and subsequently preventing PR-B-
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mediated transrepression. Alternatively, considering that ERα can also interact with NFκB (Ray et 
al. 1997), ERα may be competing with the progestogen-bound PR-B for binding to NFκB.  
Our next aim was to determine whether the ERα-specific antagonist MPP, and the ERβ-specific 
antagonist PHTPP, could modulate progestogen-induced transrepression on the endogenous NFκB-
containing IL-8 gene. We showed that the R5020-, LNG-, GES- and DRSP-induced repression of 
IL-8 gene expression is not modulated in the presence of the ERα antagonist MPP (figure 3.10C). 
However, it should be noted that MPP itself significantly downregulated the TNFα-induced IL-8 
mRNA expression. Considering that the IL-8 gene contains NFκB and AP-1 binding sites in its 
promoter (Roebuck 1999), and that the ER subtypes has also been shown to interact with the DNA-
bound NFκB transcription factor to negatively regulate gene transcription (Ray et al. 1997), it is 
possible that the antagonist bound-ERα may form a complex with the PR at the NFκB cis-elements 
upon addition of the progestogens, where it then modulates expression of the IL-8 gene. Results in 
figure 3.10D showed that PHTPP alone had no significant effect on TNFα-induced transcriptional 
activation of the IL-8 gene, while the antagonist-bound ERβ can modulate progestogen-induced 
repression of the IL-8 gene (figure 3.10D). However, as mentioned before, no definitive 
conclusions can be drawn from the endogenous IL-8 gene expression data as this is the result of a 
single experiment which needs to be repeated.  
4.6. Progestogen-induced breast cancer cell proliferation is not modulated by 
the ER subtypes 
The transcriptional regulation of several genes, whether it is via a transactivation (Nass & Dickson 
1997), transrepression (Badache & Hynes 2001) or non-genomic mechanism (Saitoh et al. 2005), 
have been shown to contribute to cellular processes such as proliferation. Numerous in vitro studies 
have investigated whether progestins can lead to breast cancer cell proliferation (Horwitz & 
Freidenberg 1985; van der Burg et al. 1992; Botella et al. 1994; Kalkhoven et al. 1994; Catherino et 
al. 1993; Krämer et al. 2006; Ruan et al. 2012), with the results often contradictory. Furthermore, 
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the majority of these studies did not directly compare the proliferative effects of progestins from 
different generations. To the best of our knowledge, our study is thus the first to directly compare 
the proliferative efficacies and potencies of select progestins from different generations to each 
other and natural Prog in the T47D breast cancer cell line. Results from colorimetric MTT assays 
showed that all progestogens, with the exception of NET-A and DRSP, displayed similar 
proliferative efficacies and potencies (figure 3.11; Table 3.3). These results are in agreement with a  
previous study showing that NET, LNG and GES stimulate cell proliferation of the HCC1500 
(Krämer et al. 2006) breast cancer cell line at concentrations of 10- and 100-fold more than used in 
our study. Additionally, 10 nM GES and MPA has previously been shown to increase cell 
proliferation in the MCF-7 (Catherino et al. 1993) and T47D (Giulianelli et al. 2012; Wargon et al. 
2014) breast cancer cell lines. 
We also investigated whether the ERα-specific and ERβ-specific antagonists could modulate 
progestogen-induced T47D breast cancer cell proliferation, and showed that the ERα-specific 
antagonist had no effect on progestogen-induced proliferation of the T47D breast cancer cells 
(figure 3.12A), while the ERβ-specific antagonist significantly increased LNG- and GES-induced 
T47D breast cancer cell proliferation (figure 3.12B).  The latter result suggests that the ERβ may 
play a protective role in LNG- and GES-induced T47D breast cancer cell proliferation.  
In summary, considering that the progestogens appear to upregulate expression of the proliferation-
related c-myc gene which is often overexpressed in cancer, while exhibiting anti-inflammatory 
effects by repressing the expression of the pro-inflammatory cytokine, IL-8 which is often 
upregulated in breast cancer, the progestogens appear to be exerting their proliferative effects via 
the transactivation function of the PR. In addition to the fact that the results on c-myc and IL-8 gene 
expression is from a single experiment, it is however important to note that the regulation of a large 
number of genes, and not only individual genes, are involved in the regulation of cellular processes 
such as proliferation. 
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4.7. Future work 
The present study has a number of shortcomings which should be addressed in future studies. The 
major limitation was that only a single realtime qPCR experiment was performed to investigate the 
effects of the different progestogens on the expression of the endogenous c-myc and IL-8 genes, 
and that the requirement of the ER was not investigated using the ER antagonist ICI 182 780. Thus, 
future studies should include at least two repeats of these experiments, in the absence and presence 
of ICI 182 780, so as to confirm the effects of the progestogens on these genes, while also 
evaluating the contribution of the ERs. However, ICI 182 780 will not discriminate between the ER 
subtypes, thus we suggest that the individual role of ERα and ERβ should also be addressed using 
siRNA technology to silence the expression of the specific ER subtype. Furthermore, as the T47D 
cells express both PR isoforms, siRNA technology could also be performed to investigate the roles 
of PR-B and PR-A in mediating the effects of the progestogens on gene expression and breast 
cancer cell proliferation. 
In terms of understanding the mechanism whereby ERα and ERβ decreased the maximal responses 
of the progestogens via PR-B on a synthetic PRE-containing promoter, we suggest that future 
research should be devoted towards investigating whether the ER subtypes form a complex with 
PR-B and whether this PR-B/ER complex co-localises to the PRE cis-element of the c-myc 
promoter. To determine whether a protein-protein interaction occurs between PR-B and ERα or 
ERβ, co-immunoprecipitation assays (Co-IP) could be performed, while chromatin 
immunoprecipitation (ChIP) assays could be used to evaluate whether the PR-B/ER complex 
occupies the PRE cis-element in the promoter of the c-myc gene. Similarly experiments can be 
performed to delineate the mechanism whereby ERα abolishes the ability of some progestogens to 
transrepress the TNFα-induced activity on the synthetic NFκB-containing promoter. Lastly, as we 
speculated that ERα downregulates PR-B protein expression while simultaneously increasing the 
basal transcriptional activity of PR-B by a mechanism involving an increase in the activity of 
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CDK2, this should be evaluated by performing an enzymatic assay to determine CDK2 activity and 
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ADDENDUM A  
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1. Media  
Luria Bertani (LB) medium 
10 g NaCl 
10 g Tryptone 
5 g yeast extract 
Adjust to final volume of 1 L using reverse osmosis (RO) water. 
Sterilize by autoclaving and store at room temperature. 
LB Agar plates 
LB medium 
15 g/L bacterial agar 
Ampicillin (final concentration 50 µg/ml) 
2. Cell lysis  
10X Tris-phosphate-EDTA (TPE) buffer 
108 g Tris (hydroxymethyl) aminomethane  
15.5 ml 85% phosphoric acid 
40 ml 0.5 M EDTA (pH 8.0) 
Adjust to final volume of 1 L using RO water. 
Sterilize by autoclaving and store at room temperature. 
Passive Lysis Buffer 
0.5 ml Triton X-100 
25 ml Glycerol 
7 ml 1X TPE buffer  
720 µl 0.5 M EDTA 
Adjust to final volume of 250 ml using RO water and store at 4°C. 
3. Electrophoresis and western blotting solutions  
10% (w/v) Sodium dodecyl sulphate (SDS) 
Dissolve 10 g SDS in 100 ml RO water at 68°C.  
Store at room temperature. 
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2X Laemmli buffer 
1 ml 1M Tris-HCl (pH 6.8) 
5 ml 10% (w/v) SDS 
2 ml Glycerol 
500 µl β-mercaptoethanol 
0.01 g bromophenol blue 
Adjust to final volume of 25 ml with RO water and store at -20°C.  
10X SDS-polyacrylamide gel electrophoresis (SDS-PAGE) running buffer 
20 g SDS 
60.6 g Tris  
288.2 g glycine 
Adjust to final volume of 2 L using RO water and store at room temperature. 
1X Transfer buffer 
6.06 g Tris 
28.83 g glycine  
200 ml methanol  
Adjust to final volume of 2 L using RO water and store at 4°C. 
10X Tris buffered saline (TBS) (pH 7.5) 
Dissolve 60.5 g Tris and 87.6 g NaCl in 800 ml RO water. 
Adjust the pH to 7.5 
Adjust to final volume of 1 L using RO water and store at 4°C. 
TBS-Tween (TBST) 
100 ml 10X TBS buffer 
1 ml Tween 20 
Adjust to final volume of 1 L using RO water and store at 4°C. 
50X Tris-acetate-EDTA (TAE) buffer 
Dissolve 242.2 g Tris in 700 ml RO water. 
Add 57.1 ml glacial acetic acid and 100 ml 0.5 M EDTA (pH 8.2). 
Adjust to final volume of 1 L using RO water and store at room temperature. 
The buffer is used for preparing and performing agarose gel electrophoresis.  
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10X Morpholinopropanesulfonic acid (MOPS) running buffer  
Dissolve 83.71 g MOPS in 800 ml DEPC-treated H2O. 
Add 33.4 ml 3 M NaOAc and 20 ml 0.5 M EDTA RNase-free stock solutions. 
Adjust pH to 7.0  
Adjust to final volume of 1 L using DEPC-treated H2O. 
Sterilize by autoclaving and store in a dark place at 4°C. 
The buffer is mainly used for the electrophoresis of denaturing formaldehyde agarose gels. 
Formaldehyde RNA loading buffer (2x): 
0.071 g bromophenol blue 
1 ml Glycerol 
1.5 ml 10X MOPS 
2.6 ml formaldehyde 
7.3 ml formamide 
Adjust to final volume of 15 ml using DEPC-treated H2O.  
Prepare 1 ml aliquots and store at -20°C. 
Add 2.5 µl ethidium bromide to each 1 ml aliquot before use. 
The buffer is used for preparation of RNA samples for denaturing formaldehyde agarose gel 
electrophoresis. 
4. Cell proliferation assay 
MTT Solution (5 mg/ml) 























Realtime qPCR is a powerful technique in which the amplification of DNA can be monitored in 
realtime (Arya et al. 2005). This is in contrast to conventional PCR where the amplified product can 
only be seen when the PCR is completed. In qPCR, the amplified DNA is labelled  with fluorescent 
dyes such as SYBR Green, which binds to the minor groove of double stranded DNA (Lekanne 
Deprez et al. 2002). It is thus possible to monitor the amplified DNA in realtime by measuring 
fluorescence throughout the PCR process. The amount of fluorescence detected during 
amplification is directly proportional to the amount of amplified DNA (Arya et al. 2005). The cycle 
number at which fluorescence is first observed is called the quantification cycle (Cq) (Pfaffl 2001).  
The current study used qPCR to detect and quantify changes in gene expression upon treatment 
with the test compounds. Before qPCR analysis could be performed it was important to isolate 
intact RNA that was of a high quality as RNA of poor quality can negatively influence the 
subsequent qPCR results. RNA purity was evaluated by measuring the optical density (OD) of the 
RNA, followed by agarose gel electrophoresis on a denaturing formaldehyde agarose gel to assess 
the quality of the RNA. An OD 260/280 ratio of 1.9 or greater is indicates pure RNA (Sambrook et 
al. 1989), while two clear 28S and 18S RNA bands, with the 28S band being approximately twice 
the intensity of the 18S band, indicates intact RNA (Krebs et al. 2009). A representative 1% 
denaturing formaldehyde agarose gel showing intact RNA is shown in Figure B1.  
 
Figure B1. A representative 1% denaturing formaldehyde agarose gel indicating intact RNA. T47D 
breast cancer cells were treated with 0.1% (v/v) EtOH (Lane 1 and 3) or 10 nM MPA (Lane 2 and 4). Total 
RNA was isolated as described in Chapter 2 Section 2.7 and 1 µg RNA was loaded onto the agarose gel. The 
RNA was visualised by ethidium bromide staining.  
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The intact total RNA isolated from the T47D cells was used to synthesize cDNA as described in 
Chapter 2 Section 2.8 and subsequently realtime qPCR was performed as described in Section 2.9 
of Chapter 2. Considering that PCR efficiency is dependent on the efficiencies of the primer sets, 
we first determined the primer efficiencies of the c-myc, IL-8 and GAPDH primer pairs. In theory, 
PCR efficiency is assumed to be two as the amount of DNA present in a sample should double with 
each PCR cycle (Pfaffl 2001; Wong & Medrano 2005). However, this is not always the case since 
the efficiency of each reaction is dependent on the efficiency of the primer set (Wong & Medrano 
2005), which may vary. Therefore, the efficiency of the respective primer pairs for c-myc, IL-8 and 
GAPDH was determined before calculating the relative expression of these genes.  
Determining primer pair efficiency 
To determine the amplification efficiency of each of the primer sets used in this study, a dilution 
series of a single cDNA sample was prepared to generate a standard curve and each dilution was 
analysed in triplicate. A no template control was also included in order to confirm that no 
contamination or primer self-amplification was present. A standard curve (Figure B2) was 
generated with the Cq values for each dilution plotted against log cDNA concentration. Using the 
following equation (Pfaffl, 2001), the slope obtained from the standard curve was used to calculate 
the exponential amplification value (E, primer efficiency) of each primer set: 
  E = 10
[-1/slope] 
(1)  
The primer efficiencies reported for the c-myc, IL-8 and GAPDH primer pairs are the averages of 
two independent experiments. The efficiencies of the primer sets used in this study can be found in 
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Figure B2. Representative standard curves generated for the (A) c-myc, (B) IL-8 and (C) GAPDH 
genes, respectively. The standard curves were obtained by plotting the cycle number (Cq) relative to log 
cDNA concentration.  
 
Melting curve analysis  
Each PCR product has a unique melting temperature which is dependent on the nucleotide content 
and the size of the amplicon (Ririe et al. 1997). A single melting peak per sample confirms the 
presence of only one PCR amplified product. If more than one peak occurs, it indicates the presence 
of primer-dimers or other non-specific products (Ririe et al. 1997; Fraga et al. 2008). Considering 
that SYBR Green binds to double stranded DNA, and that the total fluorescence measured using 
SYBR Green is the sum of the fluorescence from all double stranded DNA products formed during 
the PCR reaction, it is important to ensure that the fluorescence measured is from a single product. 
A melting curve analysis was performed by varying the temperature between 65°C and 95°C, while 
gradually increasing the temperature by 2.2°C for each step and continuously measuring the 
fluorescence. Using the LightCycler® software, a melting curve was generated by plotting the 
negative derivative of fluorescence over temperature (-dF/dT) versus temperature (
o
C) (Figure B3). 
The melting temperatures for the c-myc, IL-8 and GAPDH primers were determined to be 86.5°C, 
81.1°C and 88.0°C, respectively. Apart from performing melting curve analysis to ensure that a 
single product was amplified, agarose gel electrophoresis was performed to confirm amplicon size. 
















Figure B3. Melting curves generated for realtime qPCR products. The melting curves were generated for 
(A) c-myc, (B) IL-8 and (C) GAPDH using the LightCycler® 96 software. The negative controls containing 























































































































Stellenbosch University  https://scholar.sun.ac.za
122 
 
Figure B4. Representative agarose gels indicating the realtime qPCR end products of (A) c-myc, (B) 
IL-8 and (C) GAPDH. The products were subjected to electrophoresis on a 2% agarose gel and visualised 
using the Nancy-520 (Sigma-Aldrich, South Africa) nucleic acid stain. M: GeneRuler 100 bp DNA Ladder 
(Thermo Scientific, USA); Lane 1: no template control; Lane 2: sample treated with 1 nM R5020. 
 
Determining the relative expression levels of the genes of interest 
Having shown that a single amplicon of the correct size was amplified for all three genes, the 
relative expression levels (R) of the target genes, c-myc and IL-8, were determined by using the 
mathematical model for relative quantification described by Pfaffl (2001) in equation 2, and 
expressed as a relative ratio of target gene expression relative to the expression levels of the 
reference gene. 












(control   sample)
                                   
The R value is dependent on the primer efficiency (as calculated using equation 1) and the change 
in quantification cycle ( Cq). The  Cq can be determined by subtracting the Cq value of the sample 
treated with the test compound from the Cq value of the EtOH-treated (vehicle control) sample. A R 
value of one indicates no difference between the treated and untreated samples, while a R value of 
more than one indicates upregulation of the target gene and less than one indicate inhibition of the 
target gene (Pfaffl 2001). 
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